[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 305
1. Pacheco AJ, Torres JL, de la Guardia FV, Arrabal Polo MA, Gómez AZ: Intraparenchymatous adenomatoid tumor dependent on the rete testis: A case report and review of literature. Indian J Urol; 2009 Jan;25(1):126-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraparenchymatous adenomatoid tumor dependent on the rete testis: A case report and review of literature.
  • The adenomatoid tumor is the most frequent paratesticular tumor.
  • It is a benign tumor, which in women is mainly found in the uterus and the fallopian tubes, while in men it is most frequently found in the epididymis.
  • The clinical signs and imaging studies are, on many occasions, difficult to differentiate from malign intratesticular solid tumor, which can result in unnecessary orchidectomies.
  • We present a new case of intraparenchymatous adenomatoid tumor dependent on the rete testis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 1996;30(1):127-8 [8854081.001]
  • [Cites] J Urol. 2004 May;171(5):1765-72 [15076274.001]
  • [Cites] Urology. 1992 Oct;40(4):359-61 [1413358.001]
  • [Cites] J Clin Ultrasound. 1992 Sep;20(7):479-80 [1324954.001]
  • (PMID = 19468443.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2684313
  • [Keywords] NOTNLM ; Adenomatoid tumor / diagnosis and ultrasound
  •  go-up   go-down


2. Crippa S, Di Bella C, Faravelli A: Skin adnexal neoplasm closely resembling adenomatoid tumor: a unique occurrence. Int J Surg Pathol; 2006 Apr;14(2):177-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin adnexal neoplasm closely resembling adenomatoid tumor: a unique occurrence.
  • We describe a primary skin neoplasm located in the left chest wall that closely resembled adenomatoid tumor of male and female genital tract.
  • The tumor involved the dermis and subcutaneous tissue and measured 0.7 cm in greatest diameter.
  • We are unaware of a previous description of this morphologic pattern in a primary skin tumor, which we have interpreted as of skin adnexal and specifically of eccrine sweat gland origin.
  • [MeSH-minor] Adenomatoid Tumor / pathology. Aged. Breast Neoplasms / surgery. Carcinoma, Ductal / surgery. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703184.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T: IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol; 2010 May;41(5):745-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
  • Differentiating reactive mesothelial cells from metastatic carcinoma and malignant mesothelioma is critical in effusion cytology.
  • Numerous immunohistochemical/cytochemical reports use various antibodies in effusion samples, and most antibodies differentiate metastatic adenocarcinoma from malignant mesothelioma, but no antibodies help distinguish malignant mesothelioma from reactive mesothelial cells.
  • IMP3/L523S has been identified in several human malignant tumors.
  • A total of 229 cases of pleural and peritoneal effusion cytospecimens were evaluated for the study, including 39 benign effusions with reactive mesothelial cells and 190 metastatic malignant effusions.
  • IMP3 immunoreactivity was observed in 2 (5.1%) of 39 cases of reactive mesothelial cells, 138 (72.6%) of 190 cases of malignant effusion, 4 (36.4%) of 11 cases of malignant mesothelioma, 106 (75.7%) of 140 cases of metastatic adenocarcinoma, and 8 (100%) of 8 cases of squamous cell carcinoma.
  • In the peritoneal effusions, the sensitivity for the diagnosis of metastatic adenocarcinoma to distinguish reactive mesothelial cells was 92.3%.
  • However, the IMP3 antibody is a highly specific marker for malignant lesions, and thus, IMP3 staining is useful for distinguishing neoplastic cells from reactive mesothelial cells in effusion samples.
  • [MeSH-major] Adenocarcinoma / metabolism. Ascitic Fluid / metabolism. Biomarkers, Tumor / metabolism. Mesothelioma / metabolism. Neoplasm Proteins / metabolism. Pleural Effusion, Malignant / metabolism. RNA-Binding Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20060157.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


Advertisement
4. Terry NE, Fowler CL: Benign cystic mesothelioma in a child. J Pediatr Surg; 2009 May;44(5):e9-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cystic mesothelioma in a child.
  • Grossly, it resembled lymphangioma; however, histopathologic diagnosis was benign cystic mesothelioma (BCM), an entity that presents mainly in women of childbearing age.
  • He also underwent resection of a congenital cystic adenomatoid malformation of the right lung.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Ascites / etiology. Cystic Adenomatoid Malformation of Lung, Congenital / complications. Cystic Adenomatoid Malformation of Lung, Congenital / surgery. Diagnosis, Differential. Dyspnea / etiology. Humans. Infant. Lymphangioma / diagnosis. Male. Neoplasm Recurrence, Local / surgery. Pleural Effusion / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433159.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Garg K, Lee P, Ro JY, Qu Z, Troncoso P, Ayala AG: Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases. Ann Diagn Pathol; 2005 Feb;9(1):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases.
  • Adenomatoid tumors are relatively uncommon benign neoplasms of mesothelial origin, usually occurring in the male and female genital tracts.
  • Rare extragenital adenomatoid tumors have been identified in the adrenal glands, heart, mesentery, pleura, and lymph nodes.
  • In the adrenal gland, adenomatoid tumors may pose a diagnostic challenge.
  • Because of its glandular pattern, an adenomatoid tumor may be confused with an adenocarcinoma.
  • We present 3 cases of adrenal adenomatoid tumors, including one with a concurrent large hemorrhagic vascular adrenal cyst.
  • The adenomatoid tumors were unilateral, appeared solid and white, and varied from 1.7 to 4.2 cm in diameter.
  • One patient presented with abdominal pain due to the presence of a concurrent large adrenal cyst.
  • The tumor was an incidental radiological finding in another case and was discovered during the course of a workup for hypertension in the third case.
  • The light microscopic appearances were consistent with those of typical adenomatoid tumors.
  • Immunohistochemical stains for calretinin and cytokeratin 5/6 were positive, confirming the tumors' mesothelial origin.
  • In our experience, the key to the diagnosis of this rare benign tumor is to consider adenomatoid tumor in the differential diagnosis of any glandular tumor occurring in the adrenal gland.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Biomarkers, Tumor / metabolism. Calbindin 2. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Cysts / complications. Cysts / metabolism. Cysts / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Middle Aged. S100 Calcium Binding Protein G / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692945.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


6. Minato H, Nojima T, Kurose N, Kinoshita E: Adenomatoid tumor of the pleura. Pathol Int; 2009 Aug;59(8):567-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the pleura.
  • A case of adenomatoid tumor of the pleura is reported, and its differential diagnosis from benign and malignant pleural lesions is discussed.
  • A 7 mm, circumscribed tumor had characteristic features of adenomatoid tumor.
  • The tumor was composed of an aggregation of irregularly shaped tubulocystic spaces with fibrous stoma.
  • On immunohistochemistry the tumor cells were positive for AE1/AE3, CAM5.2, vimentin, cytokeratin 5/6, D2-40, calretinin, thrombomodulin, and WT-1, but negative for CEA, Leu M1 (CD15), thyroid transcription factor-1, epithelial membrane antigen, desmin, glucose transporter-1 (GLUT-1), CD31, and CD34.
  • Adenomatoid tumor of the pleura is rare, and the pathogenesis has not been elucidated.
  • Recognition of these benign mesothelial lesions in the pleura is important to avoid misdiagnosis.
  • The immunohistochemistry in the present case supports its mesothelial origin.
  • [MeSH-major] Adenomatoid Tumor / pathology. Neoplasms, Multiple Primary / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Dermatomyositis / complications. Esophageal Neoplasms / complications. Esophageal Neoplasms / pathology. Female. Humans. Immunohistochemistry. Incidental Findings. Liver Cirrhosis, Biliary / complications. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627540.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A, Mutti L: Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers; 2010 Jul-Sep;25(3):164-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
  • BACKGROUND: A potential role of serum osteopontin (OPN) and serum mesothelin-related peptide (SMRP) in the diagnosis of malignant pleural mesothelioma (MPM) has been recently reported.
  • Our study aimed to evaluate the influence of preanalytic variables on serum and plasma OPN, to compare serum and plasma OPN in the same population, and to assess whether OPN levels can aid in the diagnostic distinction of patients with MPM versus benign respiratory disease (BRD) and healthy subjects exposed to asbestos.
  • We measured OPN in 239 plasma samples from 207 asbestos-exposed subjects including 94 healthy controls and 113 subjects with BRD, and 32 patients with epithelial MPM, employing a commercially available ELISA.
  • Plasma and serum OPN levels were significantly higher (p<0.0001) in patients with epithelial MPM than in the healthy control group and the BRD group.
  • The application of a ROC curve for plasma OPN resulted in an AUC value of 0.780 with a best cutoff of 878.65 ng/mL, with a sensitivity of 68.8% and a specificity of 84.5%.
  • Plasma and serum OPN may be useful markers in the diagnosis of epithelial MPM in addition to traditional radiological exams.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood. Specimen Handling

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878622.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  •  go-up   go-down


8. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ: Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer; 2008 May 6;98(9):1562-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.
  • MUC1/EMA expression has been observed in the majority of epithelioid mesotheliomas.
  • However, little is known of the characteristics of MUC1/EMA in mesothelioma.
  • Herein, we studied the cell surface and soluble expression of the MUC1/EMA glycoprotein, and determined the mRNA and genomic expression profiles in mesothelioma.
  • MUC1 mRNA expression was significantly higher in mesothelioma samples than in benign mesothelial cells.
  • Seven of 9 mesothelioma samples expressed MUC1-secreted mRNA isoform in addition to the archetypal MUC1/transmembrane form.
  • CA15.3 (soluble MUC1) levels were significantly higher in the serum of mesothelioma patients than in healthy controls but were not significantly different to levels in patients with benign asbestos-related disease.
  • CA15-3 in effusions could differentiate malignant from benign effusions but were not specific for mesothelioma.
  • Thus, as in other cancers, alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for mesothelioma diagnosis and should also be investigated as a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Mucin-1 / metabolism. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1059-65 [10576665.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):139-51 [10877273.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3102-8 [11049990.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):9-16 [11162861.001]
  • [Cites] Curr Opin Mol Ther. 2001 Feb;3(1):102-5 [11249725.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):166-71 [12115565.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8 [12620150.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):289-94 [12781427.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Histopathology. 2004 Feb;44(2):147-55 [14764058.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(2):189-231 [15270554.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1131-5 [15387710.001]
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):347-54 [3899155.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):755-61 [7679050.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5847s-5851s [7493358.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:88-99 [9422093.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:111-7 [9422095.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Diagn Cytopathol. 2005 Mar;32(3):156-9 [15690334.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):63-7 [15864588.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77 [16467101.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5910-8 [16740731.001]
  • [Cites] J Urol. 2006 Jul;176(1):91-5 [16753376.001]
  • [Cites] Tumour Biol. 2000 Jul-Aug;21(4):197-210 [10867613.001]
  • (PMID = 18454162.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2391110
  •  go-up   go-down


9. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res; 2007 May 15;13(10):2928-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
  • PURPOSE: Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment.
  • We compared diagnostic and prognostic values of mesothelin and osteopontin in 172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects.
  • EXPERIMENTAL DESIGN: Osteopontin and mesothelin were assayed with commercial ELISA kits in a series of 43 patients with pleural metastases of various carcinomas, 33 patients with benign pleural lesions associated with asbestos exposure, 96 patients with MPMs, and 112 asbestos-exposed healthy subjects.
  • However, osteopontin was unable to distinguish between MPM and pleural metastatic carcinoma or benign pleural lesions associated with asbestos exposure.
  • Serum mesothelin had a good ability for diagnosing MPM but was unable to identify patients with nonepithelioid mesothelioma subtypes.
  • Survival analysis identified tumor histologic subtype along with serum osteopontin and serum mesothelin as independent prognostic factors in mesothelioma patients.
  • [MeSH-major] Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Osteopontin / blood. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504993.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


10. Kotoulas C, Fotinou M, Tsaroucha E, Konstantinou M, Lioulias A: Images in cardiothoracic surgery. Localized fibrous mesothelioma: an extremely rare benign pleural tumor. Ann Thorac Surg; 2006 Jun;81(6):2316
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in cardiothoracic surgery. Localized fibrous mesothelioma: an extremely rare benign pleural tumor.
  • [MeSH-major] Mesothelioma / radiography. Pleural Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731187.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Dishop MK, Kuruvilla S: Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children's hospital. Arch Pathol Lab Med; 2008 Jul;132(7):1079-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children's hospital.
  • OBJECTIVE: To determine the relative incidence of primary and metastatic lung tumors in children and adolescents through a single-institution case series, to compare these data to reports in the medical literature, to discuss the clinical and pathologic features of primary tumors of the tracheobronchial tree and lung parenchyma in children, and to provide recommendations for handling pediatric lung cysts and tumors.
  • DATA SOURCES: A 25-year single institutional experience with pediatric lung tumors, based on surgical biopsies and resections at Texas Children's Hospital from June 1982 to May 2007, an additional 40 lung tumors referred in consultation, and a review of the medical literature.
  • CONCLUSIONS: A total of 204 pediatric lung tumors were diagnosed at our institution, including 20 primary benign lesions (9.8%), 14 primary malignant lesions (6.9%), and 170 secondary lung lesions (83.3%).
  • The ratio of primary benign to primary malignant to secondary malignant neoplasms is 1.4:1:11.6.
  • The most common primary lung malignancies in children are pleuropulmonary blastoma and carcinoid tumor.
  • Other primary pediatric lung tumors include congenital peribronchial myofibroblastic tumor and other myofibroblastic lesions, sarcomas, carcinoma, and mesothelioma.
  • Children with primary or acquired immunodeficiency are at risk for Epstein-Barr virus-related smooth muscle tumors, lymphoma, and lymphoproliferative disorders.
  • Metastatic lung tumors are relatively common in children and also comprise a spectrum of neoplasia distinct from the adult population.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18605764.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 128
  •  go-up   go-down


12. Gill RR, Gerbaudo VH, Jacobson FL, Trotman-Dickenson B, Matsuoka S, Hunsaker A, Sugarbaker DJ, Hatabu H: MR imaging of benign and malignant pleural disease. Magn Reson Imaging Clin N Am; 2008 May;16(2):319-39, x
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of benign and malignant pleural disease.
  • Knowledge of MR imaging appearance of pleural diseases, including pleural effusions and empyema, benign and malignant pleural tumors, and especially mesothelioma, helps guide treatment decisions and surgical planning.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474335.001).
  • [ISSN] 1064-9689
  • [Journal-full-title] Magnetic resonance imaging clinics of North America
  • [ISO-abbreviation] Magn Reson Imaging Clin N Am
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA116271; United States / NCI NIH HHS / CA / R21CA116271-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


13. Shen J, Pinkus GS, Deshpande V, Cibas ES: Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol; 2009 Apr;131(4):516-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
  • We compared the effectiveness of epithelial membrane antigen (EMA) with 2 newly described markers, X-linked inhibitor of apoptosis protein (XIAP) and an isoform of glucose transporter (GLUT-1), in the distinction between malignant mesothelioma (MM) and benign effusion (BE) in body cavity fluids.
  • [MeSH-major] Glucose Transporter Type 1 / biosynthesis. Mesothelioma / diagnosis. Mucin-1 / biosynthesis. Pleural Effusion, Malignant / diagnosis. Pleural Neoplasms / diagnosis. X-Linked Inhibitor of Apoptosis Protein / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Area Under Curve. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289587.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Mucin-1; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


14. Inase N, Tominaga S, Yasui M, Tsukada Y, Oukouchi M, Miura H: [Adenosine deaminase 2 in the diagnosis of tuberculous pleuritis]. Kekkaku; 2005 Dec;80(12):731-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With regard to pleural effusion, 18 cases were transudate and 82 cases (9 tuberculous pleuritis, 27 lung cancer, 8 mesothelioma, 5 malignant diseases except lung cancer and mesothelioma, 5 benign asbestos pleurisy, 10 empyema, 10 parapneumonic effusion, one SLE, one parasitic infection, and 6 undetermined etiology) were exudates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447785.001).
  • [ISSN] 0022-9776
  • [Journal-full-title] Kekkaku : [Tuberculosis]
  • [ISO-abbreviation] Kekkaku
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Isoenzymes; 0 / TADA2A protein, human; 0 / Transcription Factors; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


15. Arunaa S, Ponniah I: Distribution pattern of the adenomatoid odontogenic tumor: a retrospective study from the files of a government teaching hospital, Tamil Nadu, Chennai, India. J Investig Clin Dent; 2010 Aug;1(1):23-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution pattern of the adenomatoid odontogenic tumor: a retrospective study from the files of a government teaching hospital, Tamil Nadu, Chennai, India.
  • AIM: To determine the distribution and clinicopathologic characteristics of adenomatoid odontogenic tumors from Tamil Nadu, India, to provide meaningful data for comparison among different population groups, mainly in the Asian context.
  • METHODS: Forty-three adenomatoid odontogenic tumors were reviewed from 493 odontogenic tumors recorded between 1970 and 2008.
  • The data pertaining to age, sex, anatomic site, associated impacted teeth and radiographic details, provisional diagnoses, and macroscopic and microscopic details of the 43 odontogenic tumors were reviewed.
  • RESULTS: The relative frequency of adenomatoid tumors comprised 8.72% of the total odontogenic tumors.
  • The age range was 9-30 years, with a mean age of 16.88 years for combined adenomatoid odontogenic tumors.
  • The mean age for other variants of adenomatoid odontogenic tumors assessed in this study differed slightly between sexes.
  • For combined adenomatoid odontogenic tumors, the male-to-female ratio was 1:1.26, and the maxilla-to-mandible ratio was 2.9:1.
  • CONCLUSION: The present study shows variations in the distribution of adenomatoid odontogenic tumors within the population assessed, but no definite conclusion emerged with regard to regional or ethnic effect.
  • [MeSH-major] Odontogenic Tumors / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 25427183.001).
  • [ISSN] 2041-1626
  • [Journal-full-title] Journal of investigative and clinical dentistry
  • [ISO-abbreviation] J Investig Clin Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Keywords] NOTNLM ; Asian / Dravidian / India / Tamil Nadu / adenomatoid odontogenic tumor
  •  go-up   go-down


16. Meirelles GS, Kavakama JI, Jasinowodolinski D, Nery LE, Terra-Filho M, Rodrigues RT, Neder JA, Bagatin E, D'ippolito G: [Asbestos-related pleuropulmonary diseases: pictorial essay]. Rev Port Pneumol; 2005 Sep-Oct;11(5):477-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleural and pulmonary asbestos-related diseases range from benign conditions, like pleural effusion and pleural plaques, to some neoplasias, such as lung cancer and malignant mesothelioma.
  • Pleural effusion is the earliest finding after asbestos exposure, but the imaging findings are not specific.
  • Rounded atelectasis is a peripheral lung collapse in these individuals, generally related to pleural disease.
  • Some neoplasias, like lung carcinoma and pleural mesothelioma, are more prevalent in asbestos-exposed subjects.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288346.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Portugal
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 38
  •  go-up   go-down


17. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B: Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol; 2005 Nov;33(5):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
  • Expression of the 67-kd laminin receptor (67-kd LR) has been reported in a wide range of carcinomas, in many of which it correlated with poor differentiation, metastasis, disease progression, and poor survival.
  • Malignant mesothelioma (MM) is a locally aggressive and highly lethal tumor of serosal cavities that is rarely associated with clinically detectable metastasis to distant organs.
  • Protein expression of the 67-kd LR was frequently detected in carcinomas (19/24 ovarian tumors, 79%; 15/38 breast tumors, 39%), but was rare in MM (2/24 cases, 8%), despite the presence of mRNA transcripts for the receptor in all 21 specimens studied using RT-PCR.
  • Nine benign effusions that were additionally studied for protein expression were uniformly negative, as were all reactive mesothelial cells in malignant effusions.
  • They additionally suggest that the failure of MM to express the 67-kd LR protein, as opposed to the frequent expression in carcinomas with proven metastatic capacity, may be one of the factors contributing to the reduced ability of the former tumor to metastasize to distant organs.
  • [MeSH-major] Adenocarcinoma / metabolism. Ascitic Fluid / metabolism. Mesothelioma / metabolism. Pleural Effusion, Malignant / metabolism. Receptors, Laminin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240397.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Laminin
  •  go-up   go-down


18. McCluggage WG, Wilkinson N: Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology; 2005 Sep;47(3):231-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ovary is a common site of metastatic tumour.
  • In many cases of ovarian metastasis there is a known history of malignancy but in other cases the ovarian tumour is the first manifestation of disease.
  • Peritoneal tumours, including primary peritoneal carcinoma, mesothelioma and intra-abdominal desmoplastic small round cell tumour, involving the ovary are also discussed, together with a variety of other rare, metastatic ovarian neoplasms.
  • Many metastatic adenocarcinomas involving the ovary, especially those exhibiting mucinous differentiation, closely mimic primary ovarian adenocarcinomas with morphologically bland areas simulating benign and borderline cystadenoma.
  • While immunohistochemistry undoubtedly has a valuable role to play and is paramount in diagnosis in some cases, the results must be interepreted with caution, especially in mucinous tumours, and within the relevant clinical context.
  • We critically discuss the value of immunohistochemistry and associated pitfalls with each tumour type described.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115224.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  • [Number-of-references] 114
  •  go-up   go-down


19. Aziz F: Radiological Findings in a case of Advance staged Mesothelioma. J Thorac Dis; 2009 Dec;1(1):46-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological Findings in a case of Advance staged Mesothelioma.
  • Chest X Ray is the initial screening test for the mesothelioma like all other the chest diseases.
  • Certain CT features help differentiate benign from malignant processes.
  • This short article highlights the salient CT appearance of mesothelioma; the most common pleural tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22263002.001).
  • [ISSN] 2072-1439
  • [Journal-full-title] Journal of thoracic disease
  • [ISO-abbreviation] J Thorac Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3256484
  • [Keywords] NOTNLM ; Advance staged Mesothelioma / Radiological Findings
  •  go-up   go-down


20. Koo PJ, Wills JS: Case 146: Benign multicystic mesothelioma. Radiology; 2009 Jun;251(3):944-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case 146: Benign multicystic mesothelioma.
  • [MeSH-major] Mesothelioma, Cystic / radiography. Mesothelioma, Cystic / ultrasonography. Peritoneal Neoplasms / radiography. Peritoneal Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474381.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


21. Kurata S, Ishibashi M, Azuma K, Kaida H, Takamori S, Fujimoto K, Kobayashi M, Hirose Y, Aizawa H, Hayabuchi N: Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease. Jpn J Radiol; 2010 Jul;28(6):446-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease.
  • PURPOSE: The aim of this study was to compare the results of semiquantitative analysis by(18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) with plasma osteopontin levels in the same asbestos-related pleural disease population.
  • MATERIALS AND METHODS: A total of 17 patients with asbestos-related pleural disease were prospectively recruited.
  • RESULTS: Malignant pleural mesothelioma (MPM) was histologically proven in 6 patients, and 11 patients had proven benign asbestos-related pleural diseases (7 pleural plaques, 4 asbestos pleurisy).
  • The SUVmax in patients with benign asbestos-related diseases was statistically positively correlated with plasma osteopontin in the same group (Spearman's r = 0.75, P < 0.05).
  • CONCLUSION: PET/CT might be more helpful than plasma osteopontin for distinguishing benign asbestos-related pleural diseases from MPM, and the SUVmax in benign asbestos-related pleural diseases may reflect changes in pleural inflammation.
  • [MeSH-major] Asbestos / toxicity. Mesothelioma / diagnostic imaging. Osteopontin / blood. Pleural Diseases / diagnostic imaging. Positron-Emission Tomography / methods. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2004 Feb;125(2):489-93 [14769729.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):266-9 [12400973.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):411-20 [18061303.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Dec;14(6):479-88 [14563350.001]
  • [Cites] J Nucl Med. 2001 Oct;42(10):1551-5 [11585872.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1362-6 [19174489.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jun;129(6):1364-70 [15942579.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):35-45 [17204697.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1144-9 [12215551.001]
  • [Cites] Eur J Radiol. 2007 Dec;64(3):356-66 [17954021.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Apr;17 (4):377-83 [10773558.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Jul;126(1):11-6 [12878934.001]
  • [Cites] Thorac Cardiovasc Surg. 2009 Jun;57(4):217-21 [19670115.001]
  • [Cites] Exp Oncol. 2004 Sep;26(3):179-84 [15494684.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S27-32 [15950796.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):995-8 [15181135.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):339-443 [17534183.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2928-35 [17504993.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Imaging. 2006 May-Jun;30(3):177-80 [16632152.001]
  • [Cites] Radiol Clin North Am. 1992 Nov;30(6):1177-89 [1410307.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • (PMID = 20661695.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  •  go-up   go-down


22. Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA: Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch; 2007 Apr;450(4):455-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.
  • Cytology allows the diagnosis of malignant mesothelioma (MM) from effusions with high specificity but low sensitivity.
  • HA was analysed in patients with histologically confirmed MM (n=162), adenocarcinoma or other malignant tumours (n=100) and in 90 patients with benign pleural diseases.
  • [MeSH-major] Hyaluronic Acid / analysis. Mesothelioma / diagnosis. Pleural Effusion / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 1977 May 2;76(3):357-61 [870264.001]
  • [Cites] Eur Respir J. 2004 Dec;24(6):1000-6 [15572545.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Jpn J Clin Oncol. 1997 Oct;27(5):293-7 [9390204.001]
  • [Cites] Arch Geschwulstforsch. 1985;55(4):259-64 [4037997.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):405-10 [11018693.001]
  • [Cites] Chest. 1988 Nov;94(5):1037-9 [3180855.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):68-73 [2731122.001]
  • [Cites] Eur Respir J. 2003 Mar;21(3):539-44 [12662014.001]
  • [Cites] Diagn Cytopathol. 1992;8(4):333-41 [1638933.001]
  • [Cites] Eur J Cardiothorac Surg. 1989;3(5):445-7; discussion 448 [2635926.001]
  • [Cites] Eur Respir J. 1990 Oct;3(9):985-6 [2289567.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1406-10 [8111707.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1224-30 [11571736.001]
  • [Cites] Cancer. 1991 May 1;67(9):2410-4 [2013045.001]
  • [Cites] Thorax. 2003 Sep;58(9):809-13 [12947146.001]
  • (PMID = 17377812.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Azure Stains; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


23. Bishay A, Raoof S, Esan A, Sung A, Wali S, Lee LY, George L, Saleh A, Baumann M: Update on pleural diseases--2007. Ann Thorac Med; 2007 Jul;2(3):128-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The basis of selection of the articles was the impact on daily practice, change in prior thinking of a disease process or specific treatment modality, as well as proper design and execution of the study.
  • 5-Amino-laevulinic acid with fluorescent light combined with white light may allow further diagnostic yield in undiagnosed pleural disease.
  • FDG-PET may allow prognostication of patients with pleural tumors.
  • Serum osteopontin levels may distinguish patients exposed to asbestos with benign disease from those with pleural mesothelioma.
  • One of the studies reviewed showed no significant difference in tract metastasis in patients with malignant mesothelioma undergoing an invasive pleural procedure with or without irradiation to the procedure site.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Feb;69(2):369-75 [10735665.001]
  • [Cites] Thorax. 2002 Dec;57(12):1005-9 [12454292.001]
  • [Cites] Am J Respir Crit Care Med. 2002 May 1;165(9):1240-4 [11991872.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1992-9 [10570423.001]
  • [Cites] Intensive Care Med. 1999 Sep;25(9):955-8 [10501751.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1682-7 [10556140.001]
  • [Cites] Am J Emerg Med. 2006 Nov;24(7):782-6 [17098097.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Oct;132(4):763-8 [17000285.001]
  • [Cites] Lancet. 2007 May 5;369(9572):1535-9 [17482984.001]
  • [Cites] Chest. 2006 Jun;129(6):1577-83 [16778278.001]
  • [Cites] Chest. 2006 Mar;129(3):783-90 [16537882.001]
  • [Cites] Chest. 2006 Mar;129(3):718-24 [16537873.001]
  • [Cites] Chest. 2006 Feb;129(2):362-8 [16478853.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1617-8 [16221786.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Chest. 2005 Aug;128(2):684-9 [16100154.001]
  • [Cites] N Engl J Med. 2005 Mar 3;352(9):865-74 [15745977.001]
  • [Cites] Respiration. 2004 Nov-Dec;71(6):559-66 [15627865.001]
  • [Cites] Photochem Photobiol. 1999 May;69(5):605-10 [10333768.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):127-32 [9583725.001]
  • [Cites] Chest. 1997 Aug;112(2):430-4 [9266880.001]
  • [Cites] Thorax. 1997 May;52(5):416-21 [9176531.001]
  • [Cites] Ann Emerg Med. 1997 Mar;29(3):312-5; discussion 315-6 [9055768.001]
  • [Cites] Chest. 1996 Jul;110(1):102-6 [8681611.001]
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] Chest. 1995 Aug;108(2):335-9 [7634863.001]
  • [Cites] Chest. 1994 Aug;106(2):342-6 [7774299.001]
  • [Cites] Ann Intern Med. 1994 Jan 1;120(1):56-64 [8250457.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Apr;105(4):743-7; discussion 747-8 [7682268.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):389-93 [8319170.001]
  • [Cites] Clin Chest Med. 1985 Jun;6(2):237-53 [3161683.001]
  • [Cites] Chest. 1990 Feb;97(2):333-7 [2137075.001]
  • [Cites] Am J Med. 1980 Oct;69(4):507-12 [7424940.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Aug 15;170(4):377-82 [15142871.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] Ann Surg. 2002 Feb;235(2):252-60 [11807366.001]
  • [Cites] Int J Clin Pract. 2001 Dec;55(10):658-60 [11777287.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] Respirology. 2001 Sep;6(3):181-5 [11555375.001]
  • [Cites] Chest. 2001 Jun;119(6):1641-6 [11399685.001]
  • [Cites] Chest. 2001 May;119(5):1516-20 [11348962.001]
  • [Cites] Chest. 2001 Feb;119(2):590-602 [11171742.001]
  • [Cites] Respir Med. 2004 Jul;98(7):579-90 [15250222.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):9-10 [15199394.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3474-8 [15161704.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):361-5 [15099946.001]
  • [Cites] Med Sci Monit. 2003 Jun;9(6):PI54-9 [12824959.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii18-28 [12728147.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii39-52 [12728149.001]
  • [Cites] Clin J Oncol Nurs. 2003 Jan-Feb;7(1):35-8 [12629932.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2002 Oct;40(10):773-5 [12487883.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):64-70 [12468344.001]
  • [Cites] Chest. 2000 Oct;118(4):1158-71 [11035692.001]
  • (PMID = 19727362.001).
  • [ISSN] 1817-1737
  • [Journal-full-title] Annals of thoracic medicine
  • [ISO-abbreviation] Ann Thorac Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2732091
  • [Keywords] NOTNLM ; Pleural / effusions / empyema / mesothelioma / pleurodesis / pneumothorax / thoracoscopy / ultrasound
  •  go-up   go-down


24. Doviner V, Maly B, Reinhartz T, Vlodavsky I, Sherman Y: Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions. Cytopathology; 2007 Feb;18(1):13-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions.
  • We investigated whether heparanase expression may serve as a reliable marker to discriminate benign mesothelial cells from malignant cells shed into body cavities.
  • Strong immunoreactivity was noted in 35 of 40 (88%) carcinoma samples and in all three malignant mesothelioma cases.
  • Only rare (<3%) reactive mesothelial cells were noted showing a faint negligible staining.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / metabolism. Epithelium / enzymology. Epithelium / pathology. Extracellular Matrix / metabolism. Exudates and Transudates / cytology. Exudates and Transudates / enzymology. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / enzymology. Gastrointestinal Neoplasms / pathology. Humans. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17250598.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


25. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Asbestos / adverse effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Neoplasm Staging. Occupational Exposure. Prognosis. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


26. Malle D, Valeri RM, Photiou C, Kaplanis K, Andreadis C, Tsavdaridis D, Destouni C: Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology. Acta Cytol; 2005 Jan-Feb;49(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the diagnostic utility of E-cadherin (E-cad), N-cadherin (N-cad) and CD44 to discriminate adenocarcinoma cells from benign and malignant mesothelial cells in body cavity fluids and to clarify the origin of cancer cells.
  • STUDY DESIGN: A total of 120 ThinPrep (Cytyc Corp., Boxborough, Massachusetts, U.S.A.) cytologic specimens of serous effusions, which included 22 cases of reactive mesothelium, 6 cases of malignant mesothelioma and 92 cases of metastatic adenocarcinoma from various sites, were immunostained for E-cad, N-cad and CD44.
  • RESULTS: Eighty-three of 92 metastatic adenocarcinomas (90.21%) expressed E-cad, while 1 of 6 malignant mesotheliomas and 1 of 22 cases of reactive mesothelium were positive for E-cad.
  • All 6 cases of mesothelioma expressed N-cad, whereas most cases of metastatic adenocarcinomas were negative.
  • CD44 immunoreactivity was seen in 18 of 22 (81.81%) benign effusions and in 21 of 92 (22.82%) metastatic adenocarcinomas.
  • CONCLUSION: The combination of E-cad, N-cad and CD44 appears to be a useful panel for distinguishing metastatic adenocarcinoma, mesothelioma and reactive mesothelium and also for clarifying the exact histogenetic origin of cancer cells.
  • This is of great importance in a few otherwise-insoluble cases because of differences in tumor treatment and prognosis.
  • [MeSH-major] Antigens, CD44 / metabolism. Biomarkers, Tumor / metabolism. Body Fluids / metabolism. Cadherins / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Mesothelioma / diagnosis. Mesothelioma / metabolism. Mesothelioma / pathology. Retrospective Studies


27. Davidson B, Dong HP, Holth A, Berner A, Risberg B: Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. Am J Clin Pathol; 2007 May;127(5):752-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells.
  • We studied chemokine receptor expression in malignant mesothelioma (MM), reactive mesothelium (RM), and leukocytes in effusions.
  • Chemokine receptors are widely expressed on leukocytes in MM and RM effusions but are infrequently found on cells of mesothelial origin.
  • This finding suggests a major role for an autocrine chemokine pathway in leukocytes but not in MM cells.
  • The increased monocyte infiltration and their higher chemokine receptor expression in MM effusions may have a tumor-promoting rather than tumor-inhibiting effect.
  • [MeSH-major] Epithelial Cells / immunology. Leukocytes / immunology. Mesothelioma / immunology. Receptors, Chemokine / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439834.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, CXCR4; 0 / Receptors, Chemokine; 0 / Receptors, Interleukin-8A
  •  go-up   go-down


28. Coskun A, Guven MA, Ozdemir O, Cirakli H, Karakus S: Benign cystic mesothelioma presenting as a huge pelvic mass--a case report. Eur J Gynaecol Oncol; 2006;27(6):621-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cystic mesothelioma presenting as a huge pelvic mass--a case report.
  • Benign cystic mesothelioma is an extremely rare peritoneal tumor.
  • It is reported in women of childbearing [corrected] age but also in males and needs a careful [corrected] differential diagnosis between benign and malign neoplasia to choose the most [corrected] adeguate therapy.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2007;28(1):3
  • (PMID = 17290598.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


29. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P: Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):646-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) results from malignant transformation of mesothelial cells.
  • Past asbestos exposure represents a major risk factor for MPM and other benign pleural disease.
  • The aim of this study was to investigate serum levels of SMRP in malignant and nonmalignant asbestos-related pleural disease.
  • PATIENTS: Four groups of patients were investigated: group 1 composed of 48 healthy subjects, group 2 composed of 177 patients with previous asbestos exposure and no pleural disease, group 3 composed of 36 patients with MPM, and group 4 composed of 101 patients with previous asbestos exposure and benign pleural disease.
  • Subjects exposed to asbestos had higher SMRP concentrations than normal control subjects regardless of the presence of pleural disease.
  • CONCLUSIONS: These data attest to good diagnostic sensitivity and specificity of SMRP for the diagnosis of malignant mesothelioma.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190155.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


30. Lanneau GS, McLaughlin D, O'Boyle J, Magann EF, Morrison JC: Well-differentiated papillary mesothelioma of the uterine serosa identified at cesarean section: a case report. J Reprod Med; 2005 Nov;50(11):860-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated papillary mesothelioma of the uterine serosa identified at cesarean section: a case report.
  • BACKGROUND: Peritoneal mesotheliomas encompass a variety of benign and malignant neoplasms.
  • Well-differentiated papillary mesothelioma (WDPM) is uncommon, is thought to be of low malignant potential and is often discovered incidentally during abdominal or pelvic surgery.
  • A 2-cm, polypoid lesion was excised from the posterior uterine fundus; final pathology showed well-differentiated papillary mesothelioma.
  • A follow-up laparoscopic examination with abdominal washing for cytology and peritoneal biopsies revealed no residual disease.
  • Knowledge of the variable disease spectrum of mesothelioma is important in patient counseling and management.
  • Differentiating between WDPM and malignant mesothelioma, other peritoneal tumors and implants from primary sites is necessary to avoid overtreatment.
  • [MeSH-major] Cesarean Section. Mesothelioma / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16419636.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Chang Q, Zhu X, Zhong YF, Ma M: Adenomatoid tumor of the suprarenal region with high plasma adrenocorticotropic hormone: a case report. Chin Med J (Engl); 2009 Nov 5;122(21):2678-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the suprarenal region with high plasma adrenocorticotropic hormone: a case report.
  • [MeSH-major] Adenomatoid Tumor / blood. Adenomatoid Tumor / diagnosis. Adrenocorticotropic Hormone / blood

  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951594.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


32. Koren J, Cunderlík P: [Adenomatoid tumor of the right adrenal gland: a case report]. Cesk Patol; 2005 Jul;41(3):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the right adrenal gland: a case report].
  • [Transliterated title] Adenomatoidný tumor pravej nadoblicky: kazuistika.
  • Adenomatoid tumor of adrenal gland is a very rare primary tumor with favourable prognosis.
  • The mesothelial origin of this tumor was confirmed by multiple studies of various authors.
  • In our case report, we present an interesting case of the adenomatoid tumor of the right adrenal gland in a 55-year-old woman.
  • Our case is the second well-documented case of this tumor occurring in a female adult patient.
  • We emphasize the presence of an intraluminal thread-like bridging strands, generally considered to be a characteristic histologic feature of this tumor, which have not yet been reported in literature in adenomatoid tumor located in adrenal glands.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16161457.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] slo
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


33. Gill RR, Gerbaudo VH, Sugarbaker DJ, Hatabu H: Current trends in radiologic management of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg; 2009;21(2):111-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current trends in radiologic management of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive pleural tumor with a complex growth pattern.
  • Perfusion CT can evaluate the microvasculature of tumors; however its disadvantages, such as high radiation exposure and side effects from iodinated contrast, have limited its use to research settings.
  • Magnetic resonance imaging (MRI) is superior to CT, both in the differentiation of malignant from benign pleural disease and in the assessment of chest wall and diaphragmatic involvement.
  • Perfusion and diffusion MRI are promising new techniques for the assessment of tumor cellularity and microvasculature and can be used for quantitative and qualitative assessment of treatment response.
  • Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for the differentiation of benign from malignant lesions, for staging, and for monitoring response to therapy.
  • PET-CT is superior to other imaging modalities in detecting more extensive disease involvement and identifying unsuspected occult distant metastases.
  • [MeSH-major] Magnetic Resonance Imaging / trends. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Positron-Emission Tomography / trends. Tomography, X-Ray Computed / trends
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Pleural Effusion, Malignant / diagnosis. Predictive Value of Tests. Radiopharmaceuticals. Thoracic Surgical Procedures. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822282.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA116271
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 30
  •  go-up   go-down


34. Moonim MT, Herbert A, Lucas SB: Benign metastasizing mesothelial cells in an axillary lymph node secondary to a chest wall fibromatosis. Histopathology; 2006 Feb;48(3):303-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing mesothelial cells in an axillary lymph node secondary to a chest wall fibromatosis.
  • [MeSH-minor] Adult. Axilla. Calbindin 2. Desmin / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / analysis. Mesothelioma / chemistry. Mesothelioma / diagnosis. Mesothelioma / pathology. Mucin-1 / analysis. S100 Calcium Binding Protein G / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430477.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calbindin 2; 0 / Desmin; 0 / Mucin-1; 0 / S100 Calcium Binding Protein G; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


35. Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol; 2010 Jan;41(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
  • We performed immunohistochemistry for napsin A and thyroid transcription factor-1 using tissue microarrays of 95 adenocarcinomas, 48 squamous cell carcinomas, 6 neuroendocrine tumors of the lung, as well as 5 colonic, 31 pancreatic, and 17 breast adenocarcinomas, 38 malignant mesotheliomas, 118 renal cell carcinomas, and 81 thyroid tumors.
  • The tissue microarrays also included 15 different benign tissues.
  • There were 13 napsin A-positive/thyroid transcription factor-1-negative and 2 thyroid transcription factor-1-positive/napsin A-negative tumors, increasing the number of cases that were positive with at least one of the markers to 81 (85%) of 95.
  • The limited number of neuroendocrine tumors tested was napsin A negative.
  • All squamous cell carcinomas, adenocarcinomas of the colon, pancreas and breast, and mesotheliomas were negative for both markers.
  • Of the renal tumors, napsin A was positive in most of papillary renal cell carcinomas (79%), about one third (34%) of clear cell renal cell carcinomas, and in a single case of chromophobe renal cell carcinoma (3%).
  • As expected, all renal tumors were thyroid transcription factor-1 negative, and all thyroid tumors, except for one papillary carcinoma, were thyroid transcription factor-1 positive.
  • The combined use of napsin A and thyroid transcription factor-1 results in improved sensitivity and specificity for identifying pulmonary adenocarcinoma in primary lung tumors and in a metastatic setting.
  • [MeSH-major] Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Nuclear Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Colonic Neoplasms / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Pancreatic Neoplasms / metabolism. Thyroid Neoplasms / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2012 Jul;43(7):1153-4; author reply 1154 [22703591.001]
  • (PMID = 19740516.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


36. Monappa V, Rao AC, Krishnanand G, Mathew M, Garg S: Adenomatoid tumor of tunica albuginea mimicking seminoma on fine needle aspiration cytology: a case report. Acta Cytol; 2009 May-Jun;53(3):349-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of tunica albuginea mimicking seminoma on fine needle aspiration cytology: a case report.
  • BACKGROUND: Adenomatoid tumor is one of the most common primary neoplasms of the paratesticular area.
  • Review of the literature showed very few reports on the cytologic features of adenomatoid tumor.
  • We report the cytologic features of a case of adenomatoid tumor arising from testicular tunica albuginea.
  • Histopathologic examination confirmed the diagnosis as adenomatoid tumor of tunica albuginea.
  • CONCLUSION: FNAC of an adenomatoid tumor poses a diagnostic challenge when the tumor arises from sites other than the epididymis because they can be mistaken for intratesticular tumors.
  • It is thus important to consider this tumor in the differential diagnosis of scrotal swellings.
  • [MeSH-major] Adenomatoid Tumor / pathology. Seminoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adult. Biopsy, Fine-Needle. Cystadenoma, Papillary / diagnosis. Diagnosis, Differential. Epithelium / pathology. Humans. Hyperplasia / diagnosis. Male. Mesothelioma / diagnosis. Orchiectomy

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534283.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Manjunath GV, Nandini NM, Sunila: Fine needle aspiration cytology of adenomatoid tumour--a case report with review of literature. Indian J Pathol Microbiol; 2005 Oct;48(4):503-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of adenomatoid tumour--a case report with review of literature.
  • Adenomatoid tumours are neoplasms of male and female genital tract with the epididymis being the most common site.
  • These benign tumours are asymptomatic or cause mild symptoms and a palpable mass.
  • Fine needle aspiration of these tumours is very useful to differentiate malignant from benign lesions and helps to avoid unnecessary aggressive surgical procedures.
  • FNAC of these benign epididymal tumours is diagnostic, rapid, reliable, conclusive and cost effective.
  • We are reporting a case of adenomatoid tumour of epididymis in a 41 year old male patient, diagnosed by FNAC and confirmed by histopathology.
  • [MeSH-major] Adenomatoid Tumor / pathology. Epididymis. Genital Neoplasms, Male / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366111.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


38. Bisceglia M, Carosi I, Scillitani A, Pasquinelli G: Cystic lymphangioma-like adenomatoid tumor of the adrenal gland: Case presentation and review of the literature. Adv Anat Pathol; 2009 Nov;16(6):424-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic lymphangioma-like adenomatoid tumor of the adrenal gland: Case presentation and review of the literature.
  • Adenomatoid tumors (AT) are usually found in the genital tract of both sexes.
  • Thirty-four cases have been reported so far, more often presenting grossly as solid tumors, rarely as solid with cystic areas, and 5 cases were almost entirely cystic.
  • On light microscopy the diagnosis may be very difficult if the tumor is rich in vacuolated cells, mimicking metastatic signet ring-cell adenocarcinoma.
  • Immunophenotyping and/or electron microscopy are paramount in helping to ascertain their mesothelial lineage.
  • Lymphangioma is the main histologic mimic of solid-cystic and cystic AT-AG, but lymphangioma is immunopositive for endothelial markers and negative for cytokeratins and mesothelial markers.
  • The adrenal tumor was 5.5 cm in size and was fully investigated immunohistochemically and ultrastructurally.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology. Lymphangioma, Cystic / pathology


39. Kalyani R, Das S: Adenomatatoid tumor: Cytological diagnosis of two cases. J Cytol; 2009 Jan;26(1):30-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatatoid tumor: Cytological diagnosis of two cases.
  • Adenomatoid tumor is a benign neoplasm of mesothelial cell origin that occurs in both male and female genital tracts.
  • Fine needle aspiration cytology has an important role in the preoperative diagnosis of the male genital adenomatoid tumor and is a rapid, reliable, conclusive, and cost-effective diagnostic tool that can be used to take appropriate surgical decisions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):495-7 [10349389.001]
  • [Cites] BJU Int. 2005 Jul;96(1):67-9 [15963123.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):6-10 [2916372.001]
  • [Cites] J Urol. 1995 Nov;154(5):1756-8 [7563340.001]
  • [Cites] Acta Cytol. 1998 Nov-Dec;42(6):1458-60 [9850662.001]
  • [Cites] AJR Am J Roentgenol. 1983 Mar;140(3):511-5 [6600544.001]
  • [Cites] J Urol. 1988 Apr;139(4):819-20 [3352056.001]
  • (PMID = 21938146.001).
  • [ISSN] 0970-9371
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167987
  • [Keywords] NOTNLM ; Adenomatoid tumor / FNAC / epididymis / testis
  •  go-up   go-down


40. Ribeiro-Silva A, Mendes CF, Costa IS, de Moura HB, Tiezzi DG, Andrade JM: Metastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases. Pol J Pathol; 2006;57(3):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological diagnoses of the primary tumor were as follows: non-Hodgkin diffuse large B-cell lymphoma (3 patients), acute mycloid leukemia (3 patients), serous papillary adenocarcinoma, well-differentiated adenocarcinoma, squamous cell carcinoma, undifferentiated neoplasm, mesothelioma, and melanoma.
  • The most common mammographic finding was a well-circumscribed mass with increased density but without speculation, calcifications or other signs that characterize the majority of primary carcinomas.
  • In conclusion, metastasis can mimic either benign disease or primary malignancy and is often an unexpected diagnosis in a patient presenting with a breast mass.
  • These masses generally indicate disseminated metastatic disease, with a very poor survival rate.
  • [MeSH-major] Breast Neoplasms / secondary. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219743.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


41. Moore AJ, Parker RJ, Wiggins J: Malignant mesothelioma. Orphanet J Rare Dis; 2008;3:34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma.
  • Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica vaginalis.
  • The exact prevalence is unknown but it is estimated that mesotheliomas represent less than 1% of all cancers.
  • Pleural malignant mesothelioma is the most common form of mesothelioma.
  • Mesothelioma is directly attributable to occupational asbestos exposure with a history of exposure in over 90% of cases.
  • There is also evidence that mesothelioma may result from both para-occupational exposure and non-occupational "environmental" exposure.
  • Idiopathic or spontaneous mesothelioma can also occur in the absence of any exposure to asbestos, with a spontaneous rate in humans of around one per million.
  • Distinguishing malignant from benign pleural disease can be challenging.
  • The most helpful CT findings suggesting malignant pleural disease are 1) a circumferential pleural rind, 2) nodular pleural thickening, 3) pleural thickening of > 1 cm and 4) mediastinal pleural involvement.
  • Involvement of a multidisciplinary team is recommended to ensure prompt and appropriate management, using a framework of radiotherapy, chemotherapy, surgery and symptom palliation with end of life care.
  • Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31 [16857795.001]
  • [Cites] Semin Diagn Pathol. 2006 Feb;23(1):56-60 [17044196.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:44 [17090323.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD005574 [17253564.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Apr;19(3):182-7 [17359904.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):666-72 [17289801.001]
  • [Cites] J Thorac Oncol. 2006 May;1(4):289-95 [17409872.001]
  • [Cites] Exp Anim. 2007 Apr;56(2):155-9 [17460361.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2928-35 [17504993.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):339-443 [17534183.001]
  • [Cites] Radiother Oncol. 2007 Jul;84(1):18-22 [17588698.001]
  • [Cites] Oncologist. 2007 Jul;12(7):850-63 [17673616.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1196-202 [17429100.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1366-74 [17674974.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):350-7 [17467922.001]
  • [Cites] Thorax. 2007 Nov;62 Suppl 2:ii1-ii19 [17965072.001]
  • [Cites] Eur Respir J. 2007 Nov;30(5):1021 [17978160.001]
  • [Cites] Occup Med (Lond). 2007 Dec;57(8):564-8 [17675661.001]
  • [Cites] Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272 [18154821.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Mayo Clin Proc. 2008 Feb;83(2):235-50 [18241636.001]
  • [Cites] Ann Thorac Surg. 2008 Mar;85(3):1049-55 [18291195.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):397-401 [18318582.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3 [18329481.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):411-20 [18061303.001]
  • [Cites] Curr Opin Pulm Med. 2008 Jul;14(4):303-9 [18520263.001]
  • [Cites] Regul Toxicol Pharmacol. 2008 Oct;52(1 Suppl):S223-31 [18022298.001]
  • [Cites] Occup Med (Lond). 2005 Mar;55(2):79-87 [15757980.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Aug;18(2):143-6 [10925221.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Toxicol Lett. 2002 Feb 28;127(1-3):251-7 [12052665.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):111-21 [12399121.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):606-16 [12573747.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii29-38 [12728148.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Ann Diagn Pathol. 2003 Oct;7(5):321-32 [14571437.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):105-19 [14730040.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] Thorax. 2004 Feb;59(2):144-8 [14760156.001]
  • [Cites] Chest. 2004 Feb;125(2):489-93 [14769729.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(1):CD002916 [14973997.001]
  • [Cites] Int J Occup Environ Health. 2004 Jan-Mar;10(1):26-39 [15070023.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Aug 15;170(4):377-82 [15142871.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1406-12 [15319247.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1157-66 [15451223.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1183-5 [15451229.001]
  • [Cites] Q J Med. 1976 Jul;45(179):427-49 [948545.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):19-25 [6174494.001]
  • [Cites] Acta Clin Belg. 1989;44(3):199-201 [2816228.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):4-9 [1689538.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):433-8 [1995528.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Nov;3(6):315-7 [1720658.001]
  • [Cites] Australas Radiol. 1994 Aug;38(3):212-4 [7524472.001]
  • [Cites] Lancet. 1995 Mar 4;345(8949):535-9 [7776771.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):370-4 [7790544.001]
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(5):317-8 [8580058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Eur Respir J. 1996 Jun;9(6):1206-10 [8804939.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):288-94; discussion 294-6 [8813257.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • [Cites] Eur J Cancer Prev. 1997 Apr;6(2):162-6 [9237066.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Thorax. 1997 Aug;52 Suppl 3:S52-7 [9381428.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):269-73 [9602260.001]
  • [Cites] Respir Med. 1998 Apr;92(4):691-2 [9659538.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4505-9 [9788590.001]
  • [Cites] Radiology. 1999 Jan;210(1):277-81 [9885620.001]
  • [Cites] Occup Environ Med. 1999 Jan;56(1):51-8 [10341747.001]
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):587-93 [15668716.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):314-20 [15780570.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2602-9 [15805256.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S109-11 [15950789.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S37-40 [15950799.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9 [16343925.001]
  • [Cites] Clin Imaging. 2006 May-Jun;30(3):177-80 [16632152.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60 [16456138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD003880 [16856023.001]
  • (PMID = 19099560.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2652430
  •  go-up   go-down


42. Van Cauwelaert Rojas R, Ruiz-Tagle Phillips D, Meneses Ciuffardi M, Carrasco Troncoso AM, Aguirre Aguirre C: [Three cases of unusual non-germ cell tumors of the testicle]. Actas Urol Esp; 2007 Sep;31(8):923-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of unusual non-germ cell tumors of the testicle].
  • By describing 3 clinical cases of unusual testicular non germinal tumors, including an adenoma of the rete testis, an undifferenciated sex cord tumor and a mesothelioma of the tunica vaginalis, we make a literature review of the unusual testicular tumors and testicular apendix, including their incidence and management.
  • Also and as one of our conclusions, we expose the importance of the intraoperatory biopsy in the testicular cancer surgery, because even if it is infrecuent, the presence of this rare testicular tumors, in which if they are proven to be benign, the testicular unit could be preserved and the radical orquiectomy could be avoided.
  • [MeSH-major] Adenoma / pathology. Mesothelioma / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18020219.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


43. Serrano Frago P, Medrano Llorente P, Borque Fernando A, Pascual Llorente M, Allue López M: [Consults by scrotum mass: epididymo lesions]. Actas Urol Esp; 2007 Apr;31(4):420-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review we try to update the knowledge about the tumors of epididymis, describing problems in diagnosis and treatment.
  • We present a case of a 39 years old patient who consults by left testicular mass, before the sonogarphy suspect of tumor was made magnetic resonance imaging , wich aimed towards tumorlike injury.
  • Excision of the injury via inguinal was made and the pathologic diagnosis was of adenomatoid tumor.
  • Owing to the few series that appear in literature, and being the commentaries of these tumors about isolated cases, we expose the characteristics of this illustrated case to value the characteristics in diagnosis and treatment to compare them with other cases.
  • [MeSH-major] Adenomatoid Tumor / diagnosis. Epididymis. Genital Neoplasms, Male / diagnosis. Scrotum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633931.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


44. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H: Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol; 2007 Dec;64(3):356-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and functional imaging of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive tumor that arises from the pleura and frequently extends to adjacent structures.
  • Major findings include nodular pleural thickening, unilateral pleural effusion, and tumor invasion of adjacent structures.
  • Perfusion CT can evaluate the microvasculature of tumors, while its disadvantages, such as high radiation exposure or side effects from iodinated contrast, limit its use in both research and clinical settings.
  • Because of its excellent contrast resolution, MRI is superior to CT, both in the differentiation of malignant from benign pleural disease, and in the assessment of chest wall and diaphragmatic involvement.
  • Perfusion MRI is the most promising technique for the assessment of the tumor microvasculature.
  • It has been shown that FDG-PET is useful for the differentiation of benign from malignant lesions, for staging and monitoring metabolic response to therapy against MPM, and that it has prognostic value.
  • An initial report on PET/CT imaging of MPM has shown increased accuracy of overall staging, improving the assessment of tumor resectability.
  • PET/CT seems to be superior to other imaging modalities in detecting more extensive disease involvement, and identifying unsuspected occult distant metastases.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging / methods. Neoplasm Staging. Neovascularization, Pathologic / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods


45. Yeh HC, Wu WJ, Lee YC, Chang TH, Huang CH, Li CC: Leiomyoma of the epididymis: a case report. Kaohsiung J Med Sci; 2006 Oct;22(10):519-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the epididymis, both primary and secondary, and whether benign or malignant, are very rare.
  • Adenomatoid tumors and leiomyoma are the most frequently diagnosed benign tumors of the epididymis.
  • In a review of the American and European literature, leiomyoma was the second most common neoplasm of the epididymis, representing 6% of primary epididymal tumors.
  • The patient presented with a 4-year history of a painless mass in the left scrotum.
  • There were no bother some symptoms except gradual enlargement of the tumor.
  • A fresh frozen section showed a benign lesion, and conservative excision of the tumor was performed without any difficulty.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17098685.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


46. Alvarez Maestro M, Tur Gonzalez R, Alonso Dorrego JM, Jesus De la Peña Barthel J, Nistal Martin De Serrano M: [Adenomatoid tumors of the epididymis and testicle: report of 9 cases and bibliographic review]. Arch Esp Urol; 2009 Mar;62(2):137-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumors of the epididymis and testicle: report of 9 cases and bibliographic review].
  • [Transliterated title] Tumor adenomatoide de epidídimo intratesticular: A proposito de nueve casos y revisión de la literatura.
  • BACKGROUND: To report the cases of adenomatoid tumors seen at Hospital Universitario La Paz in the last 15 years.
  • METHODS: A clinical, pathological, and surgical study was conducted of males with testicular or paratesticular tumors with a histological report of adenomatoid tumor.
  • RESULTS: Among the nine cases studied, seven had paratesticular and two intratesticular adenomatoid tumors.
  • Treatment of choice was mass removal for epididymal tumors and orchidectomy for intratesticular tumors.
  • CONCLUSIONS: Adenomatoid tumors are uncommon benign neoplasms of a possible mesothelial origin.
  • Because of their benign nature, the treatment of choice is local excision (conservative surgery), but orchidectomy was performed in two cases due to tumor location.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male. Testicular Neoplasms

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448282.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


47. Meignan M, Paone G: [18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease]. Rev Pneumol Clin; 2006 Apr;62(2):128-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease].
  • [Transliterated title] La tomographie par émission de positons (TEP) au 18-fluoro-déoxy-glucose (18FDG) dans l'évaluation de la pathologie pleurale maligne.
  • Use of 18FDG-PET for malignant tumors of the pleura raises certain technical difficulties because of the small size of the tumors and their diffuse distribution, but hybrid PET/CT machines offer a better localization of FDG uptake.
  • FDG-PET can discriminate between malignant and benign pleural tumors FDG uptake in the pleura is the best diagnostic criteria of malignancy.
  • The presence of FDG uptake in pleural effusion is less discriminate between benign and malignant disease.
  • For mesotheliomas, FDG-PET can difference malignant tumors from benign tumors of the pleura on the basis of the SUV value (<or > 2).
  • SUV<4 associated with an epithelial tumor is a sign of good prognosis at three years.
  • SUV > 4 associated with a non-epithelial tumor is a sign of poor prognosis.
  • For mesotheliomas, FDG uptake can be used to assess the effect of chemotherapy and determine whether patients are good responders or not.
  • [MeSH-minor] Humans. Mesothelioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670667.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 19
  •  go-up   go-down


48. Scherpereel A, French Speaking Society for Chest Medicine (SPLF) Experts Group: Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir Med; 2007 Jun;101(6):1265-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
  • Previously considered as a rare tumor, malignant pleural mesothelioma (MPM) has become a very important public health issue.
  • In fact, MPM is a tumor with a poor survival, and its incidence is expected to continue to increase for at least the next 10 years.
  • The diagnosis of MPM may be difficult because of differential diagnosis such as pleural benign disease induced by asbestos exposure or pleural metastasis of adenocarcinoma.
  • Management of patients with MPM also remains complicated because they are often referred for evaluation late in the evolution of the disease.
  • Between April 2005 and January 2006, the French Speaking Society for Chest Medicine (SPLF), in collaboration with other French scientific societies, brought together experts on mesothelioma to draw up recommendations in order to provide clinicians with clear, concise, up-to-date guidelines on management of MPM, presented in this report.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17137779.001).
  • [ISSN] 0954-6111
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 11
  •  go-up   go-down


49. Mahmood S, Martinez de Llano SR: Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT. Clin Nucl Med; 2008 Jul;33(7):510-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT.
  • A 71-year-old man with newly diagnosed malignant mesothelioma was referred for an F-18 FDG PET/CT study to evaluate the extent of disease.
  • The corresponding CT scan findings of cortical thickening and a "Swiss cheese" appearance were most consistent with Paget disease.
  • The intense FDG uptake in an osseous lesion on FDG-PET in our case reminds us of the variable nature of FDG uptake in Paget disease, the possibility of false-positive findings on FDG-PET in patients with cancer, and the usefulness of the fusion techniques in the evaluation of skeletal lesions, with the potential for discriminating between benign Paget disease and other pathologic bone findings.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / radionuclide imaging. Humerus / radionuclide imaging. Lung Neoplasms / diagnosis. Lung Neoplasms / radionuclide imaging. Mesothelioma / diagnosis. Mesothelioma / radionuclide imaging. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / radionuclide imaging. Osteitis Deformans / diagnosis. Osteitis Deformans / radionuclide imaging
  • [MeSH-minor] Aged. Fluorodeoxyglucose F18 / pharmacology. Humans. Male. Neoplasm Metastasis. Positron-Emission Tomography / methods. Radiopharmaceuticals / pharmacology. Tomography, X-Ray Computed / methods


50. Nagata S, Aishima S, Fukuzawa K, Takagi H, Yonemasu H, Iwashita Y, Kinoshita T, Wakasugi K: Adenomatoid tumour of the liver. J Clin Pathol; 2008 Jun;61(6):777-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumour of the liver.
  • An unusual primary adenomatoid tumour arising in the normal liver is described.
  • Hepatectomy was performed, and the patient is alive and free of disease 1 year postsurgery.
  • Grossly, the tumour showed a haemorrhagic cut surface with numerous microcystic structures.
  • Immunohistochemical studies showed that the epithelioid cells were strongly positive for a broad spectrum of cytokeratins (AE1/AE3, CAM5.2, epithelial membrane antigen and cytokeratin 7) and mesothelial markers (calretinin, Wilms' tumour 1 and D2-40).
  • Atypically, abundant capillaries were observed; however, the cystic proliferation of epithelioid cells with vacuoles and immunohistochemical profile of the epithelioid element were consistent with hepatic adenomatoid tumour.
  • [MeSH-major] Adenomatoid Tumor / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Calbindin 2. Hepatectomy. Humans. Immunohistochemistry. Keratins / analysis. Male. Neovascularization, Pathologic. S100 Calcium Binding Protein G / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2003 Jun;16(6):613-7 [12808068.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):969-77 [12826889.001]
  • [Cites] Urology. 1975 Nov;6(5):635-41 [1189154.001]
  • [Cites] J Pathol. 1986 Apr;148(4):327-35 [3517266.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):722-4 [17483249.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] J Clin Ultrasound. 2005 Jun;33(5):233-6 [16047378.001]
  • [Cites] Scand J Gastroenterol Suppl. 2006;(243):102-15 [16782629.001]
  • [Cites] Curr Probl Diagn Radiol. 2007 May-Jun;36(3):107-23 [17484954.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1219-23 [8827028.001]
  • (PMID = 18505892.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2569191
  •  go-up   go-down


51. Pich A, Galliano D: Pure (non-papillary) serous cystadenoma of the epididymis: a histologic and immunohistochemical study. Pathol Res Pract; 2005;201(1):65-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cystic tumor strictly attached to the head of the epididymis was surgically resected.
  • Immunohistochemical staining was positive for epithelial membrane antigen, low- and high molecular weight cytokeratins, progesterone receptor, vimentin, and S-100 protein, but was negative for carcinoembryonic antigen, CD10, p53 protein, and calretinin.
  • The differential diagnosis to spermatocele and adenomatoid tumor of the epididymis is discussed.

  • MedlinePlus Health Information. consumer health - Testicular Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807314.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


52. Podobnik J, Kocijancic I, Kovac V, Sersa I: 3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results. Radiol Oncol; 2010 Jun;44(2):92-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Fifteen patients with the asbestos-related thoracic disease were scheduled for 3T MRI.
  • Five had a benign form of the disease and 10 had malignant pleural mesothelioma (MPM).
  • From the patients with a benign form of the disease their last CT examination in digital form was acquired and patients with MPM were scheduled for CT examination with contrast media.
  • CONCLUSIONS: These preliminary results pointed out that MRI was equal or even better compared with CT examination for detecting possible malignant potential of pleural changes in the asbestos-related pleural disease, using signal intensity measurements of T2 fs-weighted images.
  • The 3T MRI enabled the accurate determination of chest pathology and it could be used for imaging of patients with the asbestos-related thoracic disease.
  • This finding turned us to propose 3T MRI imaging technique as a non-ionizing imaging method for the follow-up of patients with the isolated pleural form of the asbestos-related disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):963-8 [8610582.001]
  • [Cites] Eur Respir J. 1998 Jan;11(1):194-7 [9543293.001]
  • [Cites] Eur J Radiol. 2000 Jun;34(3):196-207 [10927161.001]
  • [Cites] Acta Radiol. 2001 Sep;42(5):502-7 [11552888.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):105-19 [14730040.001]
  • [Cites] Invest Radiol. 2004 Sep;39(9):554-64 [15308938.001]
  • [Cites] Eur Radiol. 2005 Feb;15(2):324-8 [15565313.001]
  • [Cites] Radiology. 2008 Feb;246(2):596-604 [18056854.001]
  • [Cites] Invest Radiol. 2007 Jun;42(6):377-83 [17507808.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):386-92 [17646465.001]
  • (PMID = 22933897.001).
  • [ISSN] 1318-2099
  • [Journal-full-title] Radiology and oncology
  • [ISO-abbreviation] Radiol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Other-IDs] NLM/ PMC3423685
  • [Keywords] NOTNLM ; 3T, magnetic resonance imaging / asbestos-related thoracic disease / malignant pleural mesothelioma
  •  go-up   go-down


53. Uzüm N, Ozçay N, Ataoğlu O: Benign multicystic peritoneal mesothelioma. Turk J Gastroenterol; 2009 Jun;20(2):138-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma.
  • Benign multicystic peritoneal mesothelioma is a rare tumor that occurs mainly in women in their reproductive age.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / surgery

  • Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530048.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


54. Bhalla R, Siddiqui MT, Mandich D, Cartun RW, Fiel-Gan MD, Nassar A, Mandavilli SR: Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol; 2007 Jun;35(6):342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction between malignant mesothelioma and adenocarcinoma is a diagnostic challenge in cytologic specimens of effusion fluids.
  • As for today, no single antibody has demonstrated absolute sensitivity or specificity for Mesothelioma.
  • D2-40 and podoplanin have recently been recognized to stain mesothelial cells.
  • Our aim for this study was to evaluate the utility of these two markers as indicators of mesothelial cells using cell blocks by comparison with two other established mesothelial markers.
  • A total of 40 cell blocks of effusion fluids including cases of epithelioid mesotheliomas, metastatic carcinomas and benign cases with reactive mesothelial cells were selected.
  • D2-40 and podoplanin were positive in 100% of mesothelioma cases in comparison to metastatic adenocarcinoma cases where the positivity was 0%.
  • It is concluded that D2-40 and podoplanin are very useful markers for mesotheliomas.
  • Since these markers are extremely helpful in differentiating epithelioid mesothelioma from metastatic adenocarcinoma, they shall be a valuable addition to the battery of markers used to differentiate the two entities.
  • [MeSH-major] Antibodies, Neoplasm. Mesothelioma / diagnosis. Pleural Effusion, Malignant / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497664.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm
  •  go-up   go-down


55. Ohar JA, Ampleford EJ, Howard SE, Sterling DA: Identification of a mesothelioma phenotype. Respir Med; 2007 Mar;101(3):503-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a mesothelioma phenotype.
  • Despite the strong association of asbestos exposure to mesothelioma, only a fraction of persons exposed develop this neoplasm which is characterized by long latency and shortened survival.
  • Familial clustering implicates both exposure and genetic predisposition as causative, but a biologically relevant mesothelioma phenotype essential to genetic analysis has not been defined.
  • To identify a more extensive set of traits that would define a mesothelioma phenotype for the purpose of genetic analysis, we set to determine characteristics that distinguish mesothelioma patients from others exposed to asbestos and to identify factors that predict the presence of mesothelioma over other mesenchymal tumors of the peritoneum and carcinoma metastatic to the pleura.
  • We compared demographics in four asbestos-exposed groups (controls n=347, bronchogenic cancer n=67, mesothelioma n=179 and benign asbestos-induced lung disease (BALD) n=3757).
  • Within the mesothelioma group, we compared traits to identify characteristics associated with shortened survival.
  • We found that compared to other asbestos-exposed groups, subjects with mesothelioma were younger at first asbestos exposure, had a greater risk of a second cancer diagnosis (odds ratio=3.29), had a longer disease latency, and had a greater risk of cancer among first-degree relatives (point estimate for risk 2.93; 95% CI 2.5-3.5).
  • Thoracic tumor location, work exposure and male gender were consistently associated with shortened survival (1.9+/-1.3 years).
  • We conclude that thoracic tumor location, work exposure, male gender, long latency, early age at first exposure, presence of a second cancer, and first-degree relative with cancer define a phenotype that sets mesothelioma patients with a short survival apart from other asbestos-exposed individuals.
  • [MeSH-major] Asbestos / adverse effects. Lung Neoplasms / genetics. Mesothelioma / genetics. Occupational Diseases / genetics


56. Acikalin MF, Tanir HM, Ozalp S, Dundar E, Ciftci E, Ozalp E: Diffuse uterine adenomatoid tumor in a patient with chronic hepatitis C virus infection. Int J Gynecol Cancer; 2009 Feb;19(2):242-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse uterine adenomatoid tumor in a patient with chronic hepatitis C virus infection.
  • Uterine adenomatoid tumors are usually solitary lesions.
  • Adenomatoid tumors diffusely infiltrating the entire myometrium have rarely been reported in the literature.
  • A feature common to half of the reported cases of diffuse uterine adenomatoid tumor was an immunocompromised status of the patient caused by the medications for renal transplantation.
  • In this article, we describe an unusual case of diffuse uterine adenomatoid tumor in a patient with chronic hepatitis C virus infection.
  • Pathological examination showed, in addition to multiple leiomyomas, diffuse uterine adenomatoid tumor.
  • [MeSH-major] Adenomatoid Tumor / immunology. Hepatitis C, Chronic / immunology. Immunocompromised Host. Uterine Neoplasms / immunology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396001.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Bandier PC, Hansen A, Thorelius L: [Adenomatoid tumour of the adrenal gland]. Ugeskr Laeger; 2009 Jan 26;171(5):306-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumour of the adrenal gland].
  • [Transliterated title] Adenomatoid tumor i binyre.
  • An adenomatoid tumour in the right suprarenal gland was discovered during clinical cancer staging of a 73-year-old woman.
  • Adenomatoid tumours in the suprarenal glands are rare and are most often found incidentally.
  • Differential diagnoses comprise malignant vascular neoplasm or adenocarcinoma.
  • Immunohistochemistry or electron microscopy allows uncomplicated distinction between these tumours.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ugeskr Laeger. 2009 Mar 16;171(12):1015; author reply 1015 [19306484.001]
  • (PMID = 19176156.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


58. Nagano K, Umeda Y, Senoh H, Gotoh K, Arito H, Yamamoto S, Matsushima T: Carcinogenicity and chronic toxicity in rats and mice exposed by inhalation to 1,2-dichloroethane for two years. J Occup Health; 2006 Nov;48(6):424-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 2-yr exposure to DCE produced a dose-dependent increase in incidences of benign and malignant tumors, including subcutaneous fibroma, mammary gland fibroadenoma and peritoneal mesothelioma in male rats; subcutaneous fibroma and mammary gland adenoma, fibroadenoma and adenocarcinoma in female rats; and bronchiolo-alveolar adenoma and carcinoma, endometrial stromal polyp, mammary gland adenocarcinoma and hepatocellular adenoma in female mice.
  • The types of tumors and their target organs found in this study were consistent with those observed in rats and mice administered DCE by gavage in a NCI study.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. 1,2-DICHLOROETHANE .
  • Hazardous Substances Data Bank. DICHLOROETHANE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179635.001).
  • [ISSN] 1341-9145
  • [Journal-full-title] Journal of occupational health
  • [ISO-abbreviation] J Occup Health
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Ethylene Dichlorides; 55163IJI47 / ethylene dichloride
  •  go-up   go-down


59. Pila Pérez R, Rosales Torres P, Pila Peláez R, Holguín Prieto V, Torres Vargas E: [Adenomatoid tumor of the epididymis: an infrequent case]. Arch Esp Urol; 2009 Oct;62(8):656-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the epididymis: an infrequent case].
  • [Transliterated title] Tumor adenomatoide del epidídimo: una infrecuente observación.
  • OBJECTIVES: To present a new case of adenomatoid tumor of the epididymis, the first report in our hospital since 1962.
  • METHODS: We report a clinical case with a brief bibliographic review about adenomatoid tumor of the epididymis.
  • Physical examination and ultrasound study demonstrated a tumor of 5x5x2 cm.
  • It was removed and the histopathological study was compatible with adenomatoid tumor of the epididymis.
  • CONCLUSION: The adenomatoid tumor of the epididymis is a neoplasm located in the paratesticular region, however it can be found infrequently in other sites.
  • Mesothelial origin has been mentioned and inflammation has played some role in the development of these tumors.
  • It can minimally invade adjacent structures, though it is benign without metastatic potential.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893140.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


60. Ouban A, Ahmed AA: Claudins in human cancer: a review. Histol Histopathol; 2010 01;25(1):83-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The claudins are present in variety of normal tissues, hyperplastic conditions, benign neoplasms, and cancers that exhibit epithelial differentiation.
  • Examples include the use of immunohistochemical detection of claudins to differentiate between oncocytoma and chromophobe renal cell carcinoma, endometrial endometrioid carcinoma and seropapillary carcinoma, mesothelioma and metastatic adenocarcinoma, hepatocellular and biliary tract carcinomas, and between intestinal-type and diffuse-type gastric carcinoma.
  • Thus, it seems that attempts to identify expression claudins in cancers are becoming increasingly useful in histologic diagnosis of tumors as well as means to assess patient's prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19924644.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Claudins
  • [Number-of-references] 63
  •  go-up   go-down


61. Kradin RL, Mark EJ: Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach. Semin Diagn Pathol; 2006 Feb;23(1):4-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach.
  • This paper examines the spectrum of challenges that confront the diagnostic surgical pathologist in distinguishing benign mesothelial hyperplasia from malignant mesothelioma.
  • The current state of the art with respect to the morphological, immunohistological, and molecular features that can assist in the evaluation of benign and malignant pleural disease is examined.
  • [MeSH-major] Epithelium / pathology. Mesothelioma / diagnosis. Pleura / pathology. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044190.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


62. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S: Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol; 2009 Dec;4(12):1480-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
  • In this pilot study, we investigate the role of 18F-FDG positron emission tomography/computed tomography (PET/CT) for differentiating asbestos-related benign pleural disease from malignant mesothelioma.
  • MATERIALS AND METHODS: The study population comprised 31 consecutive patients (17 malignant mesotheliomas, nine benign asbestos pleurisies, and five diffuse pleural fibrosis) with a mean age of 61 years between January 2006 and December 2008.
  • ROCs analyses for standardized uptake value (SUV) adjusted to body weight were calculated between benign and malignant pleural diseases.
  • RESULTS: 18F-FDG PET/CT imaging correctly detected the presence of malignancies in 15 of 17 patients with malignant mesothelioma for sensitivity, specificity, and overall accuracy of 88.2%, 92.9%, and 90.3%, respectively.
  • 18F-FDG PET/CT imaging correctly identified 13 of 14 cases of benign pleural disease.
  • The mean SUV values were 6.5 +/- 3.4 for malignant mesothelioma cases and 0.8 +/- 0.6 for benign pleural diseases (p < 0.001).
  • When we compared the two groups of pleural disease, a cut-off value of 2.2 for SUV gave the best accuracy with 94.1%, 100%, 100%, and 93.3% for sensitivity, specificity, positive predictive value, and negative predictive value, respectively.
  • CONCLUSION: Preliminary results of this trial provide evidence that 18F-FDG PET/CT imaging is a highly accurate and reliable noninvasive test to decide for further investigation of differentiating malignant mesothelioma from benign pleural disease.
  • [MeSH-major] Asbestos / adverse effects. Fluorodeoxyglucose F18. Mesothelioma / radionuclide imaging. Pleural Diseases / radionuclide imaging. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875971.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 1332-21-4 / Asbestos
  •  go-up   go-down


63. Wilkinson L, De P, Bloxham C: Mesothelial reaction in longstanding Crohn's ileitis simulating papillary mesothelioma. J Clin Pathol; 2008 Oct;61(10):1119-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelial reaction in longstanding Crohn's ileitis simulating papillary mesothelioma.
  • Intestinal and extraintestinal complications of Crohn's disease are well documented.
  • A rare and unusually florid mesothelial reaction in the surrounding small bowel serosa of a patient with a 2-year history of Crohn's ileitis is described.
  • The peritoneal surface of the ileal resection specimen displayed exuberant tubulo-papillary formations of the mesothelium, with superficial invasion of the underlying stroma.
  • The case demonstrates the well-recognised difficult differential diagnosis between a benign mesothelial proliferation and malignant mesothelioma in a novel clinical setting, and the diversity of the extramural manifestations of Crohn's disease.
  • [MeSH-major] Abdominal Neoplasms / pathology. Crohn Disease / pathology. Ileitis / pathology. Ileum / pathology. Mesothelioma / pathology

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820098.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Sollami S, Ben Salah I, Chelif M, Hafsia G, Ben Rhouma S, Nouira Y, Horchani A: [Intrascrotal adenomatoid tumors]. Tunis Med; 2008 Jun;86(6):626
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intrascrotal adenomatoid tumors].
  • [MeSH-major] Adenomatoid Tumor / pathology. Epididymis. Genital Neoplasms, Male / pathology. Scrotum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216473.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Tunisia
  •  go-up   go-down


65. Pinto V, Rossi AC, Fiore MG, D'Addario V, Cicinelli E: Laparoscopic diagnosis and treatment of pelvic benign multicystic mesothelioma associated with high CA19.9 serum concentration. J Minim Invasive Gynecol; 2010 Mar-Apr;17(2):252-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic diagnosis and treatment of pelvic benign multicystic mesothelioma associated with high CA19.9 serum concentration.
  • We report a case of benign multicystic mesothelioma in a 20-year-old woman referred because of amenorrhea.
  • Tumor serum markers revealed an increase in CA19.9.
  • Microscopically, cystic lesions showed mesothelium-lined cystic spaces surrounded by a delicate thin fibrovascular wall.
  • With immunohistochemistry, the tumor cells were strongly positive for cytokeratin and calretinin.
  • These aspects were suggestive of benign multicystic mesothelioma.
  • Electron microscopy confirmed the mesothelial nature of this tumor.
  • The association between benign multicystic mesothelioma and increased CA19.9 serum concentration has been described only once, in a man.
  • To our knowledge, this is the second case of benign multicystic mesothelioma associated with increased CA19.9 serum concentration and the first diagnosed in a woman.
  • In the present case, a minimally invasive laparoscopic approach enabled not only histologic diagnosis of benign multicystic mesothelioma but also its surgical treatment.
  • Although benign multicystic mesothelioma is a rare pathologic entity, it is important that sonologists include it in the differential diagnosis of diseases that manifest with ascites.
  • Furthermore, all surgeons should be aware of the macroscopic and laparoscopic appearance of the lesion, and its generally benign course.
  • [MeSH-major] CA-19-9 Antigen / blood. Laparoscopy. Mesothelioma, Cystic / pathology. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AAGL. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20226419.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


66. Butnor KJ: My approach to the diagnosis of mesothelial lesions. J Clin Pathol; 2006 Jun;59(6):564-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] My approach to the diagnosis of mesothelial lesions.
  • Mesothelial lesions pose considerable diagnostic challenges not only because benign tumours, reactive proliferations and malignant mesothelioma can mimic one another, but also because the morphological patterns displayed by malignant mesothelioma can simulate a variety of epithelial and non-epithelial malignancies.
  • Immunohistochemical markers can aid in distinguishing epithelioid malignant mesothelioma from metastatic adenocarcinoma, but because no single marker reliably separates all cases, a panel of stains is recommended.
  • Immunohistochemical studies are of more limited value in sarcomatoid malignant mesothelioma, and other features often play an essential role.
  • The separation of reactive mesothelial proliferations from malignant mesothelioma on small biopsy can be quite difficult, as distinguishing features, such as stromal invasion, often cannot be adequately assessed.
  • In adequately sampled lesions, however, the distinction between malignant mesothelioma, benign mesothelial proliferations and other tumours can be achieved in most cases by using a carefully integrated approach that incorporates clinical and radiographic data, immunohistochemical studies and, in selected cases, histochemical and ultrastructural techniques.
  • [MeSH-major] Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Cell Proliferation. Diagnosis, Differential. Epithelium / pathology. Humans

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1997 Jul;31(1):25-30 [9253621.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1399-408 [9414183.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):85-9 [9426522.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):166-9 [9490276.001]
  • [Cites] Cancer Lett. 1998 Feb 13;124(1):73-8 [9500194.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):285-92 [9580050.001]
  • [Cites] Histopathology. 1998 Mar;32(3):209-16 [9568505.001]
  • [Cites] Histopathology. 1998 May;32(5):462-72 [9639123.001]
  • [Cites] Histopathology. 2000 Sep;37(3):224-31 [10971698.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1545-9 [11090371.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):610-7 [11342772.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):246-52 [11488072.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1316-20 [11570906.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Arch Pathol Lab Med. 2001 Dec;125(12):1588-90 [11735696.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):6-10 [11796835.001]
  • [Cites] Am J Clin Pathol. 1998 Aug;110(2):191-9 [9704618.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):182-8 [9754650.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1215-21 [9777983.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):929-33 [9796717.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):313-23 [10088551.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):105-10 [15389250.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Histopathology. 2003 Mar;42(3):270-9 [12605647.001]
  • [Cites] J Pathol. 2003 Apr;199(4):479-87 [12635139.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • [Cites] J Thorac Imaging. 2003 Jul;18(3):200-3 [12867819.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] Histopathology. 2003 Nov;43(5):444-52 [14636270.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):534-40 [15087673.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):697-710 [15188136.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):449-55 [15297187.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] Am J Clin Pathol. 1976 Feb;65(2):159-67 [175652.001]
  • [Cites] Am J Pathol. 1982 Jul;108(1):80-8 [6178295.001]
  • [Cites] Am J Surg Pathol. 1982 Apr;6(3):215-22 [7102900.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):62-6 [3099726.001]
  • [Cites] Pathol Annu. 1987;22 Pt 2:91-131 [2825103.001]
  • [Cites] Ultrastruct Pathol. 1987;11(5-6):503-33 [3318058.001]
  • [Cites] Ultrastruct Pathol. 1988;12(4):367-84 [2458647.001]
  • [Cites] Pathol Annu. 1989;24 Pt 1:303-53 [2654842.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Histopathology. 2000 Apr;36(4):341-7 [10759948.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Hum Pathol. 1990 Jul;21(7):759-66 [2193875.001]
  • [Cites] Histopathology. 1992 Jan;20(1):47-51 [1310669.001]
  • [Cites] J Clin Pathol. 1992 Apr;45(4):295-8 [1577967.001]
  • [Cites] Histopathology. 1992 Nov;21(5):453-7 [1280615.001]
  • [Cites] Histopathology. 1993 Jun;22(6):601-2 [8354495.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):357-63 [7511353.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):439-45 [7513500.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):753-7 [7520015.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Semin Diagn Pathol. 1995 Feb;12(1):30-44 [7770673.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):189-94 [8607443.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1037-46 [8764740.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1147-52 [8822117.001]
  • [Cites] Ultrastruct Pathol. 2004 Jul-Aug;28(4):213-28 [15693633.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):75-9 [15722797.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Hum Pathol. 2005 May;36(5):465-73 [15948112.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):866-73 [15958850.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):34-48 [16056246.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1203-14 [9777982.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5):649-54 [10800396.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] J Postgrad Med. 2002 Jan-Mar;48(1):29-31 [12082324.001]
  • [Cites] Histopathology. 2002 Jul;41(1):42-9 [12121236.001]
  • [Cites] Histopathology. 2002 Oct;41(4):301-7 [12383211.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3443-8 [12552937.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):29-34 [10665909.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):107-12 [10697265.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):598-606 [10757409.001]
  • (PMID = 16731600.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1860395
  •  go-up   go-down


67. Vallerie AM, Lerner JP, Wright JD, Baxi LV: Peritoneal inclusion cysts: a review. Obstet Gynecol Surv; 2009 May;64(5):321-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DATA SOURCES: We searched the MEDLINE database for articles with keywords "peritoneal inclusion cyst" and "benign (multicystic) mesothelioma."
  • We suggest that the goal for such a chronic disease should not be cure, but symptomatic relief through individualization of treatment.
  • [MeSH-major] Mesothelioma, Cystic. Peritoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Obstet Gynecol Surv. 2009 Nov;64(11):769
  • (PMID = 19386139.001).
  • [ISSN] 1533-9866
  • [Journal-full-title] Obstetrical & gynecological survey
  • [ISO-abbreviation] Obstet Gynecol Surv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 59
  •  go-up   go-down


68. Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A: Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem; 2009 Jul;42(10-11):1046-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
  • We assessed comparatively the diagnostic value of two potential malignant pleural mesothelioma (MPM) markers: hyaluronic acid (HA) and soluble mesothelin.
  • MATERIALS AND METHOD: We measured serum and pleural fluid values of mesothelin and hyaluronic acid in 76 patients with MPM, 33 patients with pleural metastases of carcinomas (Mets group) and 27 patients with benign pleural effusion related to asbestos exposure (BPLAE).
  • [MeSH-major] Hyaluronic Acid / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302997.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


69. Shima M, Takahashi S, Maeda T, Masumori N, Itoh N, Tsukamoto T: [Adenomatoid tumor of the testis with testicular pain: a case report]. Hinyokika Kiyo; 2009 May;55(5):285-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the testis with testicular pain: a case report].
  • The intraoperative findings showed a small, white, elastic solid, a smooth surface tumor that originated from the tunica albuginea of the right testis.
  • It seemed to be benign macroscopically and partial orchiectomy was performed.
  • Pathohistological examination revealed an adenomatoid tumor of the testis which originated from the rete testis.
  • Adenomatoid tumor of the testis is a rare benign tumor.
  • Therefore, we should be aware that an adenomatoid tumor of the testis can be one of the differential diagnoses of acute scrotum.
  • [MeSH-major] Adenomatoid Tumor / complications. Adenomatoid Tumor / surgery. Pain / etiology. Scrotum. Testicular Neoplasms / complications. Testicular Neoplasms / surgery
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Humans. Male. Orchiectomy

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19507549.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Kim MP, Hofstetter WL: Tumors of the diaphragm. Thorac Surg Clin; 2009 Nov;19(4):521-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the diaphragm.
  • Primary tumors of the diaphragm are rare.
  • The most common benign cystic lesions of the diaphragm are bronchogenic or mesothelial cysts, while the most common benign solid lesion is a lipoma.
  • Benign tumors of the diaphragm are resected if they are symptomatic or if there is a doubt about the diagnosis.
  • Malignant tumors are treated based on histology and often with chemotherapy and/or radiation along with surgical resection if feasible.
  • Endometriosis, a benign process that metastasizes to the diaphragm, is typically treated medically; surgical ablation or resection is considered only after failed conservative treatment.
  • Surgical resection of metastatic malignant tumors, such as ovarian cancer and thymoma, as well as malignancies affecting the diaphragm by direct extension, such as mesothelioma, lung, and esophageal cancer, may provide some survival advantage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20112635.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


71. Young RH: Testicular tumors--some new and a few perennial problems. Arch Pathol Lab Med; 2008 Apr;132(4):548-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular tumors--some new and a few perennial problems.
  • The histopathology of testicular tumors is presented, emphasizing new, unusual, or underemphasized aspects.
  • Within the category of seminoma of the usual type, the recent literature has drawn attention to the presence in occasional tumors of solid or hollow tubules or spaces of varying sizes and shape that may result in cribriform or microcystic patterns, causing potential confusion with other neoplasms, most notably Sertoli cell tumor or yolk sac tumor.
  • Although regions of typical neoplasia and awareness of this phenomenon usually will be diagnostic, immunohistochemistry may play a role in excluding Sertoli cell tumor or yolk sac tumor.
  • Although immunohistochemistry can play an undoubted helpful role in this and selected other areas of testicular tumor evaluation, careful evaluation of the gross and routine microscopic features will solve the vast majority of diagnostic problems.
  • Spermatocytic seminoma remains a crucial pitfall in diagnosis, and the pathologist must always be alert to the possible diagnosis when looking at a seminomatous neoplasm, particularly in an older patient, although about one third of these tumors occur in the usual seminoma age range.
  • The enigmatic and picturesque tumor, polyembryoma, which virtually never occurs in pure form but may be a confusing component of a variety of mixed germ cell tumors, is discussed and illustrated.
  • Within the sex cord-stromal family of neoplasms, recent contributions and elaborations of unusual morphologic features of Leydig cell tumors and Sertoli cell tumors are presented.
  • The peculiar lesion, intratubular large cell hyalinizing Sertoli cell tumor, of young boys with Peutz-Jeghers syndrome, is briefly discussed.
  • Although secondary tumors to the testis have not received the same attention in the literature as the similar phenomenon in the female gonad, remarkable examples of testicular spread of diverse neoplasms, usually carcinoma but rarely melanoma, are seen, and the pathologist should be alert to this possibility, particularly when examining an unusual morphology in an older patient.
  • Finally, a few comments are made on the common paratesticular neoplasm, the adenomatoid tumor, highlighting its varied patterns and recent description of some of the issues that may arise when they undergo total or subtotal infarction.
  • [MeSH-minor] Carcinoma, Embryonal / diagnosis. Carcinoma, Embryonal / pathology. Diagnosis, Differential. Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / pathology. Humans. Male. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / pathology. Seminoma / diagnosis. Seminoma / pathology. Teratoma / diagnosis. Teratoma / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384207.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


72. Mazzetti L, Murer B, Quintavalle S, Zeni E, Miotto D, Mapp CE, De Rosa E, Boschetto P: [Lung cancer in a female non-smoker with occupational exposure to asbestos: a case report]. Med Lav; 2006 Jul-Aug;97(4):581-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumore polmonare in donna non fumatrice con esposizione professionale ad amianto: descrizione di un caso clinico.
  • Workers exposed to asbestos may develop lung and pleural diseases such as asbestosis, lung cancer, benign pleural effusion, pleural plaques and mesothelioma.
  • METHODS: The clinical and occupational history was based on the information kindly provided by the Occupational Unit of the National Health Service and on the case history of a hospital admittance in 2001, when the patient underwent surgery for lung cancer.
  • She had benign pleural effusion, pleural plaques, asbestosis and lung cancer.


73. Chapman EA, Thomas PS, Yates DH: Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. J Breath Res; 2010 Sep;4(3):034001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several diseases occur due to asbestos exposure, including malignant tumours such as malignant mesothelioma of the pleura and lung cancer, which have a very poor prognosis.
  • Asbestos inhalation may also result in more benign conditions such as asbestosis (or pulmonary fibrosis due to asbestos), pleural plaques and pleural thickening.
  • It is predicted that asbestos-associated mortality and morbidity will continue to increase, but methods for diagnosing asbestos-related disease are currently invasive and unsuitable for an increasingly elderly population.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21383477.001).
  • [ISSN] 1752-7163
  • [Journal-full-title] Journal of breath research
  • [ISO-abbreviation] J Breath Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 1332-21-4 / Asbestos
  •  go-up   go-down


74. Ruda TA, Dutta PK: Fenten chemistry of Fe(III)-exchanged zeolitic minerals treated with antioxidants. Environ Sci Technol; 2005 Aug 15;39(16):6147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Respirable mineral fibers, such as asbestos, are known to cause pleural mesothelioma, pulmonary fibrosis, and bronchial carcinoma, often years after exposure.
  • Erionite is carcinogenic, while mordenite is relatively benign.
  • [MeSH-minor] Asbestos / chemistry. Hydrogen Peroxide / chemistry. Lung Neoplasms / physiopathology. Mesothelioma / physiopathology. Oxidation-Reduction. Pulmonary Fibrosis / physiopathology

  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. ASBESTOS .
  • Hazardous Substances Data Bank. Erionite .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173575.001).
  • [ISSN] 0013-936X
  • [Journal-full-title] Environmental science & technology
  • [ISO-abbreviation] Environ. Sci. Technol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 0 / Fenton's reagent; 12445-20-4 / mordenite; 12510-42-8 / erionite; 1318-02-1 / Zeolites; 1332-21-4 / Asbestos; 3352-57-6 / Hydroxyl Radical; BBX060AN9V / Hydrogen Peroxide; E1UOL152H7 / Iron
  •  go-up   go-down


75. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer; 2008 Feb 25;114(1):49-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
  • BACKGROUND: Immunohistochemistry is helpful in distinguishing metastatic carcinoma from atypical mesothelial cells; however, it is not useful in differentiating atypical mesothelial cells from malignant mesothelial cells.
  • Using a mouse monoclonal antibody (L523S) against KOC, KOC expression was investigated in malignant tumors and reactive mesothelial cells in serous effusions.
  • METHODS: Seventy-six cases with paraffin-embedded pleural, pericardial, and peritoneal serous effusion cell blocks including 60 malignant serous effusions (11 malignant pleural mesotheliomas and 49 metastatic carcinomas) and benign pleural effusions (14 cases with reactive mesothelial cells and 2 cases with atypical cells with uncertain significance) were selected for immunohistochemical analysis with L523S, calretinin, and CK5/6.
  • RESULTS: Immunohistochemical studies showed that positive staining for KOC of variable degrees of intensity was observed in 47 of 60 cases in malignant serous effusions including 10 of 11 mesotheliomas and 36 of 49 metastatic carcinomas.
  • The associated reactive mesothelial cells were negative for KOC but positive for calretinin and CK5/6.
  • All 11 malignant mesotheliomas exhibited positivity for calretinin, and 9 of 11 cases had CK5/6 staining.
  • In addition, 16 cases that were originally diagnosed either as pleural effusions with reactive mesothelial cells (14) or atypical cells with uncertain significance (2) were also tested for KOC expression.
  • Interestingly, 3 of 16 cases exhibited various degrees of positivity for KOC, 2 of which were diagnosed as lung adenocarcinoma with a recurrence after tumor resection and 1 as malignant pleural mesothelioma.
  • CONCLUSIONS: Anti-L523S antibody is a useful marker for the detection of malignant cells in serous effusions and it can have significant utility in differentiating reactive mesothelial cells from malignant mesothelioma and metastatic carcinoma in combination with calretinin and CK5/6 staining.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / chemistry. Calbindin 2. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Pericardial Effusion / chemistry. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18098206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calb2 protein, mouse; 0 / Calbindin 2; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


76. Camparo P, Durand X, Avances C, Culine S, Segui B, Rigaud J, Membres du GELU-Groupe d'Etude des Lésions Urologiques, Membres du CCAFU: [Histological features and principles of treating testicle tumors in the elderly subject]. Prog Urol; 2009 Nov;19 Suppl 3:S142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological features and principles of treating testicle tumors in the elderly subject].
  • [Transliterated title] Particularités histologiques et principes de traitements des tumeurs du testicule du sujet âgé.
  • After the 6th decade, primitive lymphomas are the most frequent tumors of the testis (>30%).
  • Germ cell tumors, mainly seminomas, represent less than 20% cases.
  • Therapy do not differ from young adults germ cell tumors.
  • Sex cord stromal tumors, mesenchymal benign tumors, sarcomas and metastasis represent approximately 10% of cases each.
  • The one of metastasis depends on primitive tumor (prostatic or pulmonary adenocarcinoma or melanoma mainly).
  • Spermatocytic seminoma is a rare and benign tumor, if no sarcomatous component is observed.
  • Mesothelioma are also very rare and of bad prognosis.
  • This particular histological profile must be in mind when considering the appropriate therapeutic approach of testis tumors in elderly.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20123499.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Investigator] Choudat L; Priollet BC; Comperat E; Sibony M; Vassiliu V; Verkarre V; Allory Y; Ferlicot S; Molinié V; Denoux Y; Sautet A; Lesourd A; Trillet M; Petit T; Aillet G; Vieillefond A; Boccon-Gibod L
  •  go-up   go-down


77. Orki A, Akin O, Tasci AE, Ciftci H, Urek S, Falay O, Kutlu CA: The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg; 2009 Jun;57(4):217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Postoperative histopathological examination revealed malignancy in 44 cases, 25 of which were malignant mesothelioma; the remaining 39 cases were benign.
  • CONCLUSION: Our study suggests that PET-CT may be an effective tool for the differentiation of benign and malignant pleural diseases.
  • [MeSH-minor] Diagnosis, Differential. False Positive Reactions. Female. Fluorodeoxyglucose F18. Humans. Male. Mesothelioma / diagnosis. Mesothelioma / pathology. Middle Aged. Pleural Effusion / diagnosis. Pleural Effusion / pathology. Pleural Neoplasms / diagnosis. Radiopharmaceuticals. Sensitivity and Specificity. Thoracic Surgery, Video-Assisted. Thoracotomy. Tuberculosis, Pleural / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 19670115.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


78. Stroescu C, Negulescu R, Herlea V, David L, Ivanov B, Nitipir C, Popescu I: [Recurrent benign cystic peritoneal mesothelioma]. Chirurgia (Bucur); 2008 Nov-Dec;103(6):715-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent benign cystic peritoneal mesothelioma].
  • [Transliterated title] Mezoteliom multichistic peritoneal recidivat.
  • The benign cystic peritoneal mesothelioma (BCPM) is a rare neoplasm affecting mainly females at reproductive age.
  • The clinical manifestations are insidious, uncharacteristic; the benign cystic peritoneal mesothelioma is often discovered during a surgical procedure addressing another condition.
  • There are no long term studies dictating a single therapeutic attitude but a high risk of local recurrences and the possibility of transformation into malignant mesothelioma have lead to the current tendency towards an aggressive treatment of the tumor.
  • We present the case of a recurrent benign cystic peritoneal mesothelioma in a 40 years old female patient, emphasizing the therapeutic approach and the role of radical surgery in the treatment of BPCM.
  • [MeSH-major] Mesothelioma, Cystic / surgery. Neoplasm Recurrence, Local / surgery. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274921.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


79. Ng JW, Lau RL, Ng WF: Benign multicystic peritoneal mesothelioma: a diagnostic challenge. ANZ J Surg; 2006 May;76(5):421-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma: a diagnostic challenge.
  • [MeSH-major] Hernia, Inguinal / pathology. Mesothelioma, Cystic / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] ANZ J Surg. 2005 Jul;75(7):619-20 [15972062.001]
  • [ErratumIn] ANZ J Surg. 2006 Jul;76(7):651
  • (PMID = 16768710.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Australia
  •  go-up   go-down


80. Bansal A, Zakhour HD: Benign mesothelioma of the appendix: an incidental finding in a case of sigmoid diverticular disease. J Clin Pathol; 2006 Jan;59(1):108-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mesothelioma of the appendix: an incidental finding in a case of sigmoid diverticular disease.
  • Benign multicystic mesothelioma is a well recognised but rare entity.
  • The aim of this report is to describe a case of a small mesothelial proliferation of the peritoneum.
  • An operation was performed for symptomatic sigmoid diverticular disease.
  • Microscopy revealed a benign mesothelioma.
  • [MeSH-major] Appendiceal Neoplasms / diagnosis. Diverticulum / complications. Mesothelioma / diagnosis. Sigmoid Diseases / complications

  • Genetic Alliance. consumer health - Diverticular Disease.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chir Ital. 2002 Jul-Aug;54(4):569-72 [12239771.001]
  • [Cites] Am J Surg Pathol. 1986 Dec;10(12):844-54 [3789251.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):375-8 [2181883.001]
  • [Cites] J Korean Med Sci. 1989 Jun;4(2):111-5 [2597362.001]
  • [Cites] G Ital Oncol. 1989 Jan-Mar;9(1):39-42 [2707838.001]
  • (PMID = 16394291.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860251
  •  go-up   go-down


81. Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP: Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med; 2010 Mar 15;181(6):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
  • RATIONALE: Soluble mesothelin (SM) is currently the reference serum biomarker of malignant pleural mesothelioma (MPM).
  • METHODS: A total of 507 participants were enrolled in six cohorts: healthy control subjects (n = 101), healthy asbestos-exposed individuals (n = 89), and patients with benign asbestos-related disease (n = 123), benign respiratory disease (n = 46), lung cancer (n = 63), and MPM (n = 85).
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / diagnosis. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075387.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


82. Piccin A, Conneally E, Lynch M, McMenamin ME, Langabeer S, McCann S: Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia. Leuk Lymphoma; 2006 Jul;47(7):1394-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia.
  • [MeSH-major] Adenomatoid Tumor / diagnosis. Adenomatoid Tumor / drug therapy. Antineoplastic Agents / pharmacology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / pharmacology. Pyrimidines / pharmacology. Testicular Neoplasms / diagnosis. Testicular Neoplasms / drug therapy


83. Canedo-Patzi AM, León-Bojorge B, de Ortíz-Hidalgo C: [Adenomatoid tumor of the genital tract. Clinical, pathological and immunohistochemical study in 9 cases]. Gac Med Mex; 2006 Jan-Feb;142(1):59-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the genital tract. Clinical, pathological and immunohistochemical study in 9 cases].
  • [Transliterated title] Tumor adenomatoide del aparato genital, Estudio clinicopatológico e inmunohistoquímico de 9 casos.
  • OBJECTIVE: [corrected] Describe the histological andimmunohistochemicalfeatures of nine genital tract adenomatoid tumors.
  • MATERIAL AND METHODS: Nine cases of adenomatoid tumors were collected from the files of the Pathology department at a private hospital (ABC Hospital).
  • Tumors were studied from a histological and inmunohistochemical perspective.
  • Tumors were located in the uterus (seven),fallopian tube (one) and epididymis (one).
  • Tumor size ranged from 0.4 to 5.8 cm.
  • Arrangement of the neoplastic tubules around fascicles of smooth muscle; angiomatoidpattern with a peripheral location, and solid and adenoidpatterns with a central location in the tumor were some of the observed histological features.
  • Immunohistochemically all tumors exhibited strong and diffuse positivity for calretinin and AE1/AE3.
  • Thrombomodulin was positive in all tumors (focal and weak in angiomatoid pattern and diffuse and strong in adenoid and solid patterns).
  • The CK5/6 antibody was positive in seven tumors (diffuse in three and focal in four).
  • Two tumors were negative for this marker.
  • All tumors were negative for CD31.
  • CONCLUSIONS: The immunopheno type of the adenomatoid tumors in our series confirms their mesothelial origin.
  • [MeSH-major] Adenomatoid Tumor / pathology. Epididymis. Fallopian Tube Neoplasms / pathology. Genital Neoplasms, Male / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548294.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


84. Hayes SJ, Clark P, Mathias R, Formela L, Vickers J, Armstrong GR: Multiple adenomatoid tumours in the liver and peritoneum. J Clin Pathol; 2007 Jun;60(6):722-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple adenomatoid tumours in the liver and peritoneum.
  • [MeSH-major] Adenomatoid Tumor / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Feb;36(2):109-15 [10672054.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):548-9 [11257637.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1523-7 [12409730.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):969-77 [12826889.001]
  • [Cites] J Obstet Gynaecol Res. 2003 Aug;29(4):234-8 [12959144.001]
  • [Cites] Urology. 1973 Aug;2(2):192-5 [4769525.001]
  • [Cites] J Reprod Med. 1976 Dec;17(6):342-4 [1003400.001]
  • [Cites] Cancer. 1979 May;43(5):1678-81 [156063.001]
  • [Cites] Am J Clin Pathol. 1981 Nov;76(5):627-35 [7293978.001]
  • [Cites] Histopathology. 1988 May;12(5):555-8 [3294158.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):357-63 [7511353.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1219-23 [8827028.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1378-80 [9351577.001]
  • [Cites] Cancer. 1963 Nov;16:1497-500 [14086582.001]
  • [Cites] J Urol. 1964 Sep;92:210-4 [14213538.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):866-73 [15958850.001]
  • (PMID = 17483249.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1955065
  •  go-up   go-down


85. Jenkins LA, O-Yurvati AH: Solitary fibrous pleural tumor. J Am Osteopath Assoc; 2008 Jun;108(6):307-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous pleural tumor.
  • Solitary fibrous pleural tumors are rare masses of mesenchymal origin that may be mistaken for mesothelioma.
  • A positive staining of vimentin, negative staining of cytoplasmic keratin, and expression of the CD34 antigen can confirm the presence of a solitary fibrous pleural tumor.
  • Although most tumors of this type are benign, they possess a malignant potential and thus should be excised.
  • We report a case of a 63-year-old man who had an inconclusive biopsy of a lung lesion 15 years ago.
  • Further testing after excision revealed a solitary fibrous pleural tumor.
  • A brief discussion of the clinical presentation and incidence of these tumors is included.
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587079.001).
  • [ISSN] 1945-1997
  • [Journal-full-title] The Journal of the American Osteopathic Association
  • [ISO-abbreviation] J Am Osteopath Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Soini Y, Talvensaari-Mattila A: Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. Int J Gynecol Pathol; 2006 Oct;25(4):330-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types.
  • Strong expression of claudins 1, 4, and 7 was seen in benign and malignant epithelial ovarian tumors.
  • Expression of claudin 5, reported to be mainly present in endothelial cells, was seen in ovarian epithelial tumors, but with a significantly lower frequency than claudins 1, 4, and 7.
  • On the contrary, sex-cord stromal tumors and cysts, such as fibromas/thecomas, Sertoli-Leydig cell tumors, granulosa cell tumors, and follicular and luteinized cysts were mainly negative for claudins 1, 4, 5, and 7.
  • Interestingly, adenomatoid tumors did not express claudin 5, which is in agreement with their non-endothelial nature.
  • They were also negative for claudin 4, but expressed claudins 1 and 7, but to a lesser degree than epithelial lesions.
  • In immature teratomas, the epithelial component was usually positive whereas other components were negative for these claudins.
  • The results show that claudins 1, 4, and 7 are mainly expressed in ovarian epithelial tumors and can thus be used to indicate epithelial differentiation in them.
  • Eventhough considered an endothelial marker, claudin 5 was also present in a subset of epithelial lesions.
  • However, this claudin can be used to differentiate adenomatoid tumors from vascular lesions.
  • No significant difference was seen between epithelial benign and malignant lesions, except for claudin 5, which seemed stronger in malignant epithelial tumors.
  • [MeSH-minor] Adenomatoid Tumor / chemistry. Brenner Tumor / chemistry. Carcinoma / chemistry. Claudin-1. Claudin-4. Claudin-5. Claudins. Dysgerminoma / chemistry. Female. Humans. Immunohistochemistry. Krukenberg Tumor / chemistry. Ovarian Cysts. Sex Cord-Gonadal Stromal Tumors / chemistry. Teratoma / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990707.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudin-5; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


87. Murray J, Nelson G: Health effects of amosite mining and milling in South Africa. Regul Toxicol Pharmacol; 2008 Oct;52(1 Suppl):S75-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Research has shown that amosite produces both benign and malignant disease.
  • The risk of disease associated with amosite exposure is difficult to quantify.
  • [MeSH-major] Asbestos, Amosite / adverse effects. Asbestosis / etiology. Environmental Exposure / adverse effects. Mesothelioma / chemically induced. Mining

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. AMOSITE ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023950.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mineral Fibers; 12172-73-5 / Asbestos, Amosite
  •  go-up   go-down


88. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H: Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol; 2005 Mar;32(3):151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
  • The morphological evaluation of cytological specimens from body cavity fluids presents difficulties in the differential diagnosis between benign reactive mesothelial (RM) cells and adenocarcinoma (AC) or malignant mesothelioma (MM).
  • A total of 134 cytological specimens of serous effusions from 80 ACs, 50 RMs, and 4 MMs, previously stained with Papanicolaou stain, were selected retrospectively from our files and stained with anti-human mesothelial cell (HBME-1), calretinin, epithelial specific antigen (MOC-31), Ber-EP4, and BG8.
  • Statistical significance was found with HBME-1, calretinin, MOC-31, anti-human epithelial antigen (Ber-EP4), and blood group related antigen (BG8) when comparing AC vs. any type of mesothelial proliferation (MM or RM).
  • The sensitivity of HBME-1 and calretinin for mesothelial cells was 98 and 100%, respectively, and the specificity was 71 and 80%, respectively.
  • Both antibodies stained reactive mesothelial as well as MM cells, with calretinin showing a stronger intensity of immunostaining.
  • Our data suggest that immunocytochemical studies performed on Papanicolaou-stained cytological smears with HBME-1, calretinin, MOC-31, Ber-EP4, and BG8 proved to be useful in the differentiation between metastatic AC and mesothelial proliferation.
  • Probably, calretinin is a more preferred marker for mesothelial cells as evidenced by a more intense staining reaction.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ascitic Fluid / pathology. Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Pericardial Effusion / pathology. Pleural Effusion / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690338.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


89. Sangoi AR, McKenney JK, Schwartz EJ, Rouse RV, Longacre TA: Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases. Mod Pathol; 2009 Sep;22(9):1228-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases.
  • Adenomatoid tumors of the female and male genital tracts are well characterized as mesothelial in origin, but a detailed histological and immunohistochemical analysis comparing both traditional and newer mesothelial markers across gender and site has not been formally conducted.
  • A variety of morphologic features previously described as characteristic of adenomatoid tumors were evaluated in 44 adenomatoid tumors from the male and female genital tracts.
  • All (n=44) the adenomatoid tumors from both the female and male genital tracts demonstrated a distinctive thread-like bridging strand pattern.
  • Lymphoid aggregates were seen in all 12 adenomatoid tumors of male patients, but in only 4 of 32 (13%) tumors in female patients (P<0.0001).
  • The remaining morphologic features were variably present with no clear sex predilection.
  • Pankeratin, calretinin, and D2-40 reactivity were identified in all female (n=32) and male (n=12) genital tract adenomatoid tumors.
  • Adenomatoid tumors expressed WT-1 in 11/12 (92%) male patients and in 31/32 (97%) female patients.
  • In male patients, reactivity for CK5/6 and caldesmon was found in 1/12 (8%) and 0/12 (0%) adenomatoid tumors (respectively), whereas reactivity in female patients was found in 5/32 (16%) and 1/32 (3%); respectively.
  • Female tumors differ from their male counterparts by the frequent absence of lymphoid aggregates and the presence of a circumscribed margin when occurring in the fallopian tube.
  • Of the putative mesothelial markers evaluated, calretinin, D2-40, and WT-1 show a similar immunoprofile and have a higher sensitivity than CK5/6 and caldesmon in genital tract adenomatoid tumors.
  • [MeSH-major] Adenomatoid Tumor / pathology. Biomarkers, Tumor / analysis. Genital Neoplasms, Female / pathology. Genital Neoplasms, Male / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543245.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


90. Zimmerman RL, Fogt F: nm23 is expressed in reactive mesothelium and is not useful for detection of malignant cells in serous effusions. Oncol Rep; 2006 Jan;15(1):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] nm23 is expressed in reactive mesothelium and is not useful for detection of malignant cells in serous effusions.
  • The cytological dilemma of distinguishing malignant cells from proliferating mesothelium has generated volumes of research but no clear consensus regarding an optimal staining panel. nm23 has been frequently described in malignant cells as a metastasis suppressor, but its mechanism of action and the relationship between nm23 expression, metastases, and prognosis is controversial.
  • One hundred samples of effusions (56 malignant and 44 benign) were immunostained with nm23 using the biotin-avidin technique and diaminobenzidine as a chromogen.
  • From the malignant cases, 51 of 56 cases were positive for nm23 in at least 5% of malignant cells, while 27 of 44 reactive mesothelium cases were also positive in at least 5% of cells.
  • Its relatively high rate of expression in reactive mesothelium supports previous studies that suggest nm23 is expressed in proliferating cells.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Carcinoma / diagnosis. Nucleoside-Diphosphate Kinase / metabolism
  • [MeSH-minor] Body Fluids / enzymology. Epithelium / enzymology. Epithelium / pathology. Humans. Immunohistochemistry. Mesothelioma / diagnosis. NM23 Nucleoside Diphosphate Kinases. Serous Membrane / enzymology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328038.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  •  go-up   go-down


91. de Keizer B, Arsos G, Smit JW, Lam MG, Rinkes IH, Goldschmeding R, van Isselt JW: I-131 accumulation in a benign cystic mesothelioma in a patient with follicular thyroid cancer. Thyroid; 2008 Mar;18(3):369-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] I-131 accumulation in a benign cystic mesothelioma in a patient with follicular thyroid cancer.
  • We report a case of focal I-131 accumulation in a benign cystic mesothelioma in a patient with follicular thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Iodine Radioisotopes. Mesothelioma, Cystic / radionuclide imaging. Peritoneal Neoplasms / radionuclide imaging. Thyroid Nodule / radionuclide imaging. Tomography, Emission-Computed, Single-Photon / adverse effects

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298317.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


92. Timonera ER, Paiva ME, Lopes JM, Eloy C, van der Kwast T, Asa SL: Composite adenomatoid tumor and myelolipoma of adrenal gland: report of 2 cases. Arch Pathol Lab Med; 2008 Feb;132(2):265-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite adenomatoid tumor and myelolipoma of adrenal gland: report of 2 cases.
  • Adenomatoid tumor and myelolipoma are benign, hormonally inactive tumors that are often incidental findings in the adrenal glands.
  • Myelolipoma is more common than adenomatoid tumor in this location but both are rare, and as yet, the pathogenesis of both remains unclear.
  • We report 2 cases of composite adenomatoid tumor and myelolipoma, incidentally found in the adrenal gland on investigation for other diseases.
  • To our knowledge, composite adenomatoid tumor and myelolipoma of adrenal gland has not been previously reported.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251587.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Hasteh F, Lin GY, Weidner N, Michael CW: The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol; 2010 Apr 25;118(2):90-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
  • BACKGROUND: The distinction of benign from malignant mesothelial proliferations in cytologic specimens can be problematic.
  • METHODS: Archival paraffin-embedded cell blocks of pleural and peritoneal fluids from 52 patients with malignant mesothelioma (MM) and 64 patients with reactive mesothelial hyperplasia (MH) were retrieved.
  • IHC stains included desmin, epithelial membrane antigen (EMA), glucose-transport protein 1 (GLUT-1), Ki67, and p53.
  • EMA was positive in 9% (6 of 64) of benign and 100% (52 of 52) of malignant cases (P < .001).
  • GLUT-1 was positive in 12% (5 of 43) of benign and 47% (7 of 15) of malignant cases.
  • Ki67 showed strong nuclear positivity in >40% of mesothelial cells in 9% (6 of 64) of benign and 16% (8 of 49) of malignant cases (P = .38).
  • p53 showed strong nuclear positivity in 2% (1 of 46) of benign and 47% (7 of 15) of malignant cases (P < .001).
  • Likewise, strong membranous positivity for GLUT-1 and/or strong nuclear staining for p53 favors a mesothelioma.
  • [MeSH-major] Ascitic Fluid / metabolism. Epithelium / pathology. Immunohistochemistry. Mesothelioma / diagnosis. Pleural Effusion / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Desmin / analysis. Excitatory Amino Acid Transporter 2 / analysis. Female. Humans. Hyperplasia / pathology. Male. Middle Aged. Mucin-1 / analysis. Tumor Suppressor Protein p53 / analysis


94. Cagle PT, Churg A: Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med; 2005 Nov;129(11):1421-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
  • CONTEXT: Although much of the pathology literature focuses on differential diagnosis of diffuse malignant mesothelioma from other types of cancer, the primary diagnostic challenge facing the pathologist is often whether a mesothelial proliferation on a pleural biopsy represents a malignancy or a benign reactive hyperplasia.
  • DESIGN: Based on previous medical publications, extensive personal consultations, and experience on the United States-Canadian Mesothelioma Reference Panel and the International Mesothelioma Panel, salient information was determined about interpretation of benign versus malignant mesothelial proliferations on pleural biopsies.
  • RESULTS: Differentiation of benign reactive mesothelial hyperplasia from diffuse malignant mesothelioma is often difficult.
  • Benign reactive mesothelial hyperplasia may mimic many features ordinarily associated with malignancy, and diffuse malignant mesothelioma may be cytologically bland.
  • Entrapment of benign reactive mesothelial cells within organizing pleuritis may mimic tissue invasion.
  • CONCLUSIONS: Various histologic clues favor a benign over a malignant mesothelial proliferation and vice versa.
  • Invasion is the most reliable criterion for determining that a mesothelial proliferation is malignant.
  • When there is any doubt that a pleural biopsy represents a malignancy, we recommend a diagnosis of atypical mesothelial proliferation.
  • [MeSH-major] Epithelium / pathology. Mesothelioma / pathology. Pleura / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Hyperplasia / pathology. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253023.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


95. Chung CT, Santos Gda C, Hwang DM, Ludkovski O, Pintilie M, Squire JA, Tsao MS: FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol; 2010 Jul;63(7):630-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.
  • AIMS: To develop a fluorescence in-situ hybridisation (FISH) assay for detecting p16/CDKN2A deletion on paraffin tissue sections for use as an ancillary test to distinguish reactive from malignant mesothelial proliferations.
  • METHOD: Dual-colour FISH for p16/CDKN2A and chromosome 9 (CEP-9) was performed on 11 benign mesothelial proliferations and 54 malignant pleural mesothelioma (MPM) cases to establish cut-off values for p16/CDKN2A deletion.
  • RESULTS: Cut-off values for p16/CDKN2A deletion were calculated based on FISH signalling patterns obtained from the benign controls (mean percent nuclei plus three standard deviations).
  • None of the benign cases showed a homozygous deletion pattern (no p16/CDKN2A, at least one CEP-9 signal).
  • CONCLUSION: Distinction between benign and malignant mesothelial proliferations can be diagnostically challenging.
  • [MeSH-major] Gene Deletion. Genes, p16. In Situ Hybridization, Fluorescence / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4547-51 [12907630.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] J Pathol. 2003 Nov;201(3):355-62 [14595746.001]
  • [Cites] J Pathol. 1992 May;167(1):1-4 [1320670.001]
  • [Cites] Virchows Arch. 2008 Dec;453(6):627-35 [18958493.001]
  • [Cites] J Pathol. 1992 Dec;168(4):377-81 [1484319.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Hum Pathol. 1994 May;25(5):443-8 [8200637.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5547-51 [7923195.001]
  • [Cites] Oncogene. 1995 Aug 3;11(3):511-5 [7630635.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):649-53 [9466670.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):143-8 [15571800.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3303-8 [15867227.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):320-4 [16240396.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2970-9 [16540645.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] Histopathology. 2006 Dec;49(6):561-8 [17163840.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):215-20 [17192790.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):742-7 [18327208.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2108-13 [12796375.001]
  • [Cites] Cancer. 2003 Feb 25;99(1):51-6 [12589646.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1127-30 [12117769.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] J Pathol. 1999 Oct;189(2):251-7 [10547583.001]
  • [Cites] J Pathol. 1992 May;167(1):5-8 [1352542.001]
  • (PMID = 20591913.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Other-IDs] NLM/ PMC2989172
  •  go-up   go-down


96. Cakir C, Gulluoglu MG, Yilmazbayhan D: Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology; 2006 Feb;38(1):10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations.
  • AIMS: The differential diagnosis of malignant mesothelioma (MM) from benign mesothelial lesions (BML) based on histopathological criteria is sometimes not satisfying and causes diagnostic problems for histopathologists.
  • METHODS: Sixty-six cases of MM (33 epithelioid, 30 biphasic and 3 sarcomatoid) and 22 cases of BML (15 reactive mesothelial proliferations and 7 fibrous pleuritis/pericarditis) were included in this study.
  • CONCLUSION: As a result, being cheap and simple methods, Ki-67 and hTERT immunohistochemistries can be used in differentiating malignant and benign mesothelial lesions in routine formalin-fixed, paraffin-embedded material.
  • [MeSH-major] Cell Proliferation. Neoplasms, Mesothelial / metabolism. Neoplasms, Mesothelial / pathology. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Pleurisy / diagnosis. Pleurisy / metabolism. Pleurisy / pathology. Predictive Value of Tests. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484001.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


97. Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N: Malignant mesothelioma. Intern Med J; 2010 Nov;40(11):742-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma.
  • Malignant mesothelioma (MM) is an aggressive tumour that commonly affects the mesothelial surfaces of the pleural and peritoneal cavities, and occasionally, the tunica vaginalis and the pericardium.
  • Formerly a rare tumour, MM is increasing in incidence in Australia due to the heavy nationwide use of asbestos from 1940 until the 1980s.
  • Definitive pathological diagnosis is required and it often requires an experienced pathologist to differentiate MM from other benign or malignant processes.
  • [MeSH-major] Asbestos / toxicity. Environmental Exposure / adverse effects. Mesothelioma / epidemiology. Mesothelioma / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Internal Medicine Journal © 2010 Royal Australasian College of Physicians.
  • (PMID = 20298508.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


98. Langer J, Cohen HL: Case 1: Diagnosis: Paratesticular adenomatoid tumor. Ultrasound Q; 2006 Jun;22(2):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case 1: Diagnosis: Paratesticular adenomatoid tumor.
  • [MeSH-major] Adenomatoid Tumor / ultrasonography. Testicular Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16783220.001).
  • [ISSN] 0894-8771
  • [Journal-full-title] Ultrasound quarterly
  • [ISO-abbreviation] Ultrasound Q
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Pitta X, Andreadis E, Ekonomou A, Papachristodoulou A, Tziouvaras C, Papapaulou L, Sapidis N, Chrisidis T: Benign multicystic peritoneal mesothelioma: a case report. J Med Case Rep; 2010;4:385
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma: a case report.
  • INTRODUCTION: We report the case of a patient with a benign multicystic peritoneal mesothelioma and describe its appearance on computed tomography scans and ultrasonography, in correlation with gross clinical and pathological findings.
  • Abdominal ultrasonography and computed tomography demonstrated the presence of a large cystic mass in her left upper abdomen, adjacent to her left hemidiaphragm.
  • Pathological analysis showed a benign multicystic peritoneal mesothelioma.
  • CONCLUSIONS: Benign multicystic peritoneal mesothelioma is a rare lesion with a non-specific appearance on imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114811.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2999614
  •  go-up   go-down


100. Motamedi MH, Shafeie HA, Azizi T: Salvage of an impacted canine associated with an adenomatoid odontogenic tumour: a case report. Br Dent J; 2005 Jul 23;199(2):89-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage of an impacted canine associated with an adenomatoid odontogenic tumour: a case report.
  • The adenomatoid odontogenic tumour (AOT) has been known by a number of descriptive names (adenoameloblastoma, ameloblastic adenomatoid tumour, glandular ameloblastoma, and adenomatoid ameloblastoma) since it was first reported and later recognised as a distinct odontogenic lesion unrelated to ameloblastoma.
  • Although it was considered to be a variant of ameloblastoma at one time leading surgeons to perform unduly aggressive surgery, the treatment outcome experience has borne out the benign, nonaggressive nature of this lesion.
  • The AOT is now considered to be a hamartoma with completely benign behaviour.
  • Thus, it appears needless to extract involved anterior teeth associated with the tumour, especially in children.
  • We have not found such a procedure to have been done for this tumour in the literature.
  • [MeSH-major] Cuspid / pathology. Mandibular Neoplasms / complications. Odontogenic Tumors / complications. Tooth Movement / methods. Tooth, Impacted / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041334.001).
  • [ISSN] 0007-0610
  • [Journal-full-title] British dental journal
  • [ISO-abbreviation] Br Dent J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement